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  A Novel cardiac function of SUMO2/3 and SENP5 dependent 
pathway and its physiologic impact on congestive 
cardiomyopathy 
Publication No.___________ 
Eun Young Kim, M.S. 
Supervisory professor: Robert J. Schwartz, Ph.D. 
SUMOylation regulates diverse cellular processes including transcription, cell 
cycle, protein stability, and apoptosis. Although SUMO1 has been extensively 
studied so far, relevance of SUMO2/3 is unclear, especially in heart. Here we 
show that failing heart induces SUMO2/3 conjugation. Increased SUMO2/3-
dependent modification leads to congestive heart disease such as cardiac 
hypertrophy by promoting cardiac cell death. Calpain2 and Calpastatin as a novel 
SUMO2 targets have been known to be involved in mitochondrial-independent 
cell death pathway in heart. These SUMOylations of Calpain2 and Calpastatin 
facilitate activation of Calpain2 by reducing inhibitory role of Calpastatin. These 
findings identify a SUMO2/3-dependent modification as a novel posttranslational 
modification that controls Calpain2-Calpastatin system resulting in cardiac protein 
degradation. On the other hand, transgenic mice overexpressing SENP5, 
SUMO2/3-specific deconjugation enzyme in the heart, developed dilated 
cardiomyopathy. This unexpected phenotype mimics human heart failure, which 
has elevated SENP5 protein levels. Dilated hearts of SENP5 transgenic mice 
	   vii	  
showed markedly reduced functions of mitochondrial complexes due to almost 
complete loss of mitochondrial cristae, and compromised cardiac energy 
metabolism. These hearts also showed increased deSUMOylation of 
mitochondrial proteins including dynamin related protein (Drp1), which leads to 
nuclear translocation of mitochondrial apoptosis inducing factor (AIF). This 
induces massive loss of cardiomyocytes via caspase-independent apoptotic 
pathway. These findings identify a novel SENP5-mediated deSUMOylation 
pathway that controls mitochondrial structure and pathological remodeling of the 
heart. Thus, inhibiting SENP5 might be beneficial to dilated cardiomyopathy and 
heart failure. 
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1.1. Overview of SUMOylation  
SUMO pathway.  Precise and specific control of proteins in multicellular 
organisms is important for proper biologic function during entire life span. Protein 
modifications called PTM are most widely used to maintain physiologic 
homeostasis. These include the covalent attachment of sugars, lipids or chemical 
groups such as phosphate, acetyl or methyl groups into proteins. PTM is also 
critical for spatial and temporal modulation of protein function. Ubiquitylation has 
been well known to study as protein-based modification, involving in protein 
degradation largely by tagging as a mark to be recognized by proteasome. Nearly 
two decades after discovering Ubiquitin, SUMO, another Ubiquitin-related 
modification, has been identified. SUMO stands for Small Ubiquitin-like Modifier 
and the attention on SUMO has not been so long. Its unstable attachment to 
proteins and loss of association during experimental treatments make it difficult to 
find its existence. In addition, most of SUMOylation-dependent modification has 
been found in an association with nuclear pore component Ran GTPase 
activating protein (RanGAP1) (1, 2), indicating its difficulty to search for various 
targets. SUMO is evolutionally conserved from yeast to mammals and involved in 
the reversible and covalent attachment to targets. SUMOylation pathway is very 
similar to its biochemical analog, Ubiquitylation (3, 4). Human cells have four 
distinct SUMO isoforms: SUMO1-SUMO4 (5-7). SUMO1 to 3 are ubiquitously 
expressed. SUMO4 has been detected in limited tissues including kidney, spleen 
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and lymph node. However, substrate and function for SUMO4 has remained 
unclear (8-11). SUMO isoforms are expressed immaturely, in which their C-
terminals are stretched. Mature isoforms expose diGlycine (Gly-Gly) motif, serving 
as an active acceptor to attach with free amino group (NH2) of lysine within the 
substrates through isopeptide bond. SUMOylation predominatly occurs at a 
consensus motif (ΨKXD/E, where Ψ indicates a large hydrophobic residue such 
as I, V or L, K is the target lysine but X can be any amino acid) in target proteins, 
(7, 12). This consensus motif contributes to specificity of SUMO targets and to 
better regulatory mechanism. More extended SUMOylation motifs are 
summarized in Table 1. Mature SUMO isoforms show very similar 3D structures 
of ubiquitin in spite of less amino acid homology (3, 4, 13). This similarity causes 
competition and/or interchange for substrate affinity. Sequential SUMOylation 
cascade requires three enzymes (Figure I.1.): an E1 activating enzyme, an E2 
conjugating enzyme, and SUMO E3 ligase. The first step is initiated from 
exposure of C-terminal diGlycine morif of SUMO. SAE1/2, SUMO activating 
enzyme, then, is able to associate with mature SUMO by consuming ATP, 
resulting in transfering SUMO to Ubc9, E2 conjugating enzyme. Finally SUMO is 
facilitated to conjugate with substrates by E3 ligases including PIAS (Protein 
Inhibotor of Activated STAT) family, RanBP2, polycomb 2 and MAPL 
(Mitochondrial-Anchored Protein Ligase) (14-17). Compared to ubiquitin pathway, 
SUMO is conjugated by fewer enzymes including Ubc9, only identified veterbrate 
E2 enzyme and about 12 SUMO E3 enzymes (18). This limitation promotes 
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increasing usage of each SUMO components by distinct cellular occupancy, 
specificity and efficient combinatorial coordination. Emerging evidences suggest 
that non-covalent interaction of SUMO isoforms with substrates also occurs (19-
21). In that concept, SIM (SUMO-interacting motif) could also modulate targets 
through conformational changes (19, 22). Short hydrophobic peptides of SIM 
primarily consisting of acidic and/or phosphorylated serine residiues determine 
specificity of SUMO binding and control conformation of SUMO-SIM interactions 
(7, 20, 23). Diverse ways of SUMOylation allows SUMO-dependent PTM to 
regulate target proteins more efficiently (Figure I.2). 
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Table I.1. Motifs of SUMO conjugation. Ψ indicates any large hydrophobic 
residue, X, any residue, RanGAP, Ran GTPase activating protein; MEF2a, 
myocyte enhancer factor 2A; AR, androgen receptor; HlC1, hypermethylated in 
cancer 1; NDSM, negative-charge dependent SUMOylation motif; PDSM, 
phosphorylation-dependent SUMOylation motif. Diagram was adopted from 
Henley et al. (2007), permission #3203140162941. 
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Figure I.1. Reversible Sumoylation pathway. All SUMO paralogues are 
synthesized as precursors and matured by specific SUMO proteases, SENPs. 
SENPs also efficiently cleave the isopeptide bond between SUMO and its target. 
Both the released SUMO and the target become available for additional rounds of 
SUMOylation. Figure was modified from Melchior et al. (2008), permission 
#3196680378058.
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Figure I.2. Diverse consequences of SUMOylation. SUMOylation modulates 
target molecules by three different ways. a. SUMO-conjugation to target inhibits 
the binding of partner. In this case, the target interacts with binding partner only in 
the absence of SUMOylation. b. SUMO-conjugation triggers binding of partner 
with target, in which case SUMOylation serves as platform for better binding. SIM 
is a good example.  c. Conformational change of target is induced by 
SUMOylation. Diagram was adopted from Melchior et al. (2007), permission 
#3196681235089. 
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deSUMOylation pathway. SUMO-dependent PTM is very reversible by SENPs, 
Sentrin/SUMO specific proteases. SENPs have been identified from cleavage 
assay within bacterial transformants expressing yeast proteins and sequence 
homology search using Ubiquitin-like protein (Ulp) domain (24). SENP family 
consists of 6 isoforms (SENP1-3, SENP5-7 in human), representing high 
homology with yeast Ulp1 and 2 (Figure I.3). Yeast Ulp1 deletion mutant is lethal 
whereas Ulp2 deletion in yeast can survive but shows abnormal growth and 
hypersensitivity to DNA damage. Each human isoform has been catagorized by 
its enzymatic activity in terms of SUMO maturation and isopeptide cleavage, and 
their activity towards SUMO isoforms (Table I.2). SENP1 and 2 predominatly 
existing in the nucleus have shown the substrate preferency to all SUMO isoforms 
whereas SENP3 and 5 show a preference to only SUMO2 and 3. SENP6 and 7 
have preferentially modified SUMO2/3 conjugates. Unlike other SENPs, they 
seem to be involved in SUMOylated chain editing rather than deconjugation 
pathway. C-terminal of SENPs is relatively conserved whereas N-terminal regions 
are variable. Thus, less conserved N-terminal region of SENPs plays a key role in 
subcellular localization and substrate specificity. SENP1 has been typically 
observed in nucleus although It has both nuclear localization signal (NLS) and 
nuclear export signal (NES) (25-27). Along with these NLS and NES, SENP1 has 
also been shown to shuttle between cytoplasm and nucleus in CV-1 cells (28). 
SENP2 also contains both NLS and NES, and has been shown in nuclear 
envelope (29, 30). Later, SENP2 has also been discovered as shuttling between 
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cytoplasm and nucleus. Mutations in NES has shown to block its shuttling. 
Interestingly, cytoplasmic SENP2 has been known to be polyubiquitinated, easily 
leading to 26S proteasome degradation (31). Interestingly, SENP2 splicing 
variants have been localized in different subcellular areas. Axam, a SENP2 
splicing variant, is found in nucleoplasmic face of nuclear pore complx (NPC), and 
Axam2 and SuPr-1, other SENP2 splicing variants are able to be localized in the 
cytoplasm and promyelocytic leukaemia (PML) body of the nucleus (31-33). 
These diverse subcellular occupancies upon each alternative splices underscore 
the notion that each variant contributes to modulating specific substrates and/or to 
finetuning regulation strategy. SENP3 and SENP5 have been predominantly 
located in nucleolus but increasing evidence providing no limitation in subcellular 
localization (34, 35). Shuttling of SENP5 between nucleus and cytoplasm, or 
between nucleus and mitochondria has been known to be in a cell cycle 
dependent manner, or for mitochondrial fragmentation (36, 37). SENP6 has been 
primarily detected in cytoplasm but recent report shows its existence in the 
nucleus (38-40). Complexity of subcellular localization and distinctive enzymatic 
activity of SENPs suggest that spatial and temporal process of deSUMOylation 
may be critical to regulate the function of SUMOylated proteins.  
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Table I.2. SENPs localization and substrate specificity. Diagram was modified 
from Baek et al. (2009) and Hochstrasser et al. (2012), permission 
#3196670151606, #3200861147118.
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Figure I.3. Structural comparison of SENPs. Conserved catalytic domain is 
represented as CD. White empty boxes indicate non-conserved N-terminal region. 
Specifically, SENP6 and 7 has divided conserved catalytic domain. The function 
of N-terminal region is unknown but it is involved in distinct subcellular 
localization. Diagram was adopted from Baek et al. (2009) and Salvesen et al. 
(2008), permission #3203140609653, #3203140976954. 
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Interestingly, SENP2 splicing variants have been localized in different subcellular 
areas. Axam, a SENP2 splicing variant, is found in nucleoplasmic face of nuclear 
pore complx (NPC), and Axam2 and SuPr-1, other SENP2 splicing variants are 
able to be localized in the cytoplasm and promyelocytic leukaemia (PML) body of 
the nucleus (31-33). These diverse subcellular occupancies upon each alternative 
splices underscore the notion that each variant contributes to modulating specific 
substrates and/or to finetuning regulation strategy. SENP3 and SENP5 have been 
predominantly located in nucleolus but increasing evidence has provided no 
limitation in subcellular localization (34, 35). Shuttling of SENP5 between nucleus 
and cytoplasm, or between nucleus and mitochondria has been known to be in a 
cell cycle dependent manner, or for mitochondrial fragmentation (36, 37). SENP6 
has been primarily detected in cytoplasm but recent report shows its existence in 
the nucleus (38-40). Complexity of subcellular localization and distinctive 
enzymatic activity of SENPs suggest that spatial and temporal process of 
deSUMOylation may be critical to regulate the function of SUMOylated proteins.  
Biologic significance of SUMO pathway. Most components of SUMOylation 
associated with conjugation and deconjugation are localized in nucleus. Therefore 
their functions were relatively well understood in cell cycle, DNA repair, 
transcriptional regulation, and chromatin remodeling (41). Recent studies have 
been proposed additional role of SUMOylation process outside of the nucleus. For 
instance, GLUT1 and GLUT4, glucose transporters, in plama membrane have 
been known to be SUMOylated, resulting in opposite outcomes in terms of 
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transporter activity (42). Extranuclear functions of SUMOylation are summarized 
in Figure I.4. A variety of targets of SUMOylation suggest that SUMO-dependent 
modification is tighly associated with broad spectrum of biological events including 
apoptosis, genomic stability, gene expression, metabolism, signaling cascade, 
cell cycle, ion channel, mitochondrial dynamics (10, 43). 
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Figure I.4. Diverse functions of SUMOylation pathway. SUMO conjugation is 
dynamic and reversible. The role can be elevated or reduced by many different 
factors to modulate the activity of the targets. Thus SUMO-dependent PTM 
contributes to a variety of cellular phenomena. Diagram was modified from Henley 
et al. (2007), permission #3196671495501.  
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1.2. SUMO2/3 
      Each SUMO isoform represents substrate specificities although there is an 
overlapped preference to substrates. Since identified in yest genetics, genes 
associated with SUMO and its related components have been proven to be critical 
for cellular homeostasis in mammals (43, 44). Haploinsufficiency of murine 
SUMO1 has suggested its involvement in human cleft lip and palate through 
modification of Eya1 (45). In contrast, another study has reported that genetic 
ablation of SUMO1 in mice has not shown any lethality, although there is a 
variability of lethality depending on genetic background. This may suggest 
redundant role of SUMO2/3 for SUMO1 target (46). Although it is necessary to 
examine the role of SUMO2/3 using mice lacking genes encoding SUMO2 and/or 
3, these paradoxical results about SUMO1 deficient mice could be explained at 
least in part by following characteristics of SUMO2/3. In normal condition, 
compared to SUMO1, SUMO2/3 is detected as unconjugated form, a readily 
conjugated form upon various stresses including heat shock, oxidative stress, and 
ethanol exposure (47). This suggests that SUMO2/3 may have more active 
response upon environmental stimulation than those of SUMO1. Moreover, the 
SUMO consensus motif in the N-terminal region (Lys 11) makes SUMO2/3 
distinct from SUMO1 (48-51). PolySUMOylation by SUMO2/3 has facilitated 
ubiquitin-mediated degradation including PML by activating RNF4, ubiquitin E3 
ligase (52-54) and BMAL, a core component of circadian rthythm (55). These 
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indicate that SUMO2/3-dependent conjugation mediates distinctive biological 
functions. A recent finding has provided a new connection of SUMO2/3 with 
chromatin remodeling (56). SUMOylation of CoREST1, a transcriptional cofactor 
by SUMO2/3 suggests that SUMO2/3 may participate in gene regulation (56).  
1.3. SENP5 
      SENP5 has both C-terminal hydrolase activity for maturation of SUMO 
isoforms and isopeptidase activity for SUMO deconjugation. In spite of its dual 
enzymatic activity, it has preference of SUMO3 hydration and SUMO2/3 
deconjugation in vitro (35, 57). Strong endopeptidase activity of SENP5 (58) 
indicates that SENP5 might play a role for SUMOylation repression. Although it 
has dual enzymatic activities, SENP5 reveals less isopeptidase activity compared 
to SENP2. In addition, among SUMO isoforms, SENP5 has SUMO2/3 preference 
shown in biochemical study (35) but, selected preference does not seem to be  
restricted in vivo. Athough Drp-1, mitochondrial fission protein, has been shown to 
be modified by SUMO1, it becomes deconjugated by SENP5 (37, 59). Most 
components of SUMO pathway have been found in nucleus. Thus, their functional 
studies have been best characterized for nuclear proteins (39, 57). SENP5 has 
been also considered as a nucleolar protein based on fluorescent substrates such 
as SUMO2/3 in nucleus and N-terminal nucleolar localization sequence (49, 50, 
57). N-terminal deletion mutant of SENP5 has led to disappear its predominant 
nucleolar localization and triggered deSUMOylation activity (57). Diverse 
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subcellular localizations of SENP5 have been further supported. Majority of 
SENP5 has been detected in cytoplasm of tumor cells, although normal epithelial 
cells show its equal distribution in both nucleus and cytoplasm (60). Moreover, 
mitochondrial fraction from COS-7 cells has reasonable level of SENP5 (30)(37). 
These suggest that SENP5 shuttle between nucleus and mitochondria to be 
involved in subcellular specific modulation of targets.  
1.4. Congestive cardiomyopathy 
      The heart is a muscle organ to pump blood via circulatory system for oxygen 
and nutrients delivery and exchange carbon dioxide back to the lung. 
Cardiomyocytes generate most of contractile powers in hearts by well-organized 
contractile units called sarcomeres. Although there are other cell types consisting 
of the heart including fibroblasts, endothelial cells and immune cells, 
cardiomyocytes as contractile cells are terminally differentiated. Therefore, the 
heart loses cell proliferation ability soon after birth, although a recent report has 
discovered a very low level of cardiomyocyte turnover throughout life (61-63). 
Thus, it could respond only by increasing cardiomyocyte size to improve 
workloads (Figure I.5). Initially cardiac hypertrophy is beneficial because it is an 
adaptive response to reduce overloaded stress, but sustained hypertrophic 
growth finally leads to heart failure and sudden death. Heart develops 
hypertrophic growth in response to pathologic stimuli, resulting in fibrosis, dilation, 
ventricular remodeling and impaired cardiac output ((64-66). In constrast, there is 
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a physiologic hypertrophy that occurs as adaptive response to continuous 
physiologic stresses such as exercise and pregnancy (Figure I.6). Physiologic 
hypertrophy is fundamentally different from pathologic hypertrophy, which does 
not lead to disease state. Rather, physiologic hypertrophy undergoes more 
beneficial response to maintain stable cardiac function through specific molecular 
pathways. Pathologic hypertrophy could be characterized by several alterations. 
First, sarcomeric proteins including α-actinin are rearranged to strengthen 
contractile power, of which failing hearts have reduced level. Second, expression 
of fetal cardiac genes is reactivated. Fetal gene reprogramming includes atrial 
natriuretic factor (ANF), brain natriuretic peptide (BNP), β-myosin heavy chain (β-
MHC) and skeletal α-actin (Sk-actin) (67). Thus, fetal cardiac gene expression is 
used as indicator of pathologic hypertrophy in spite of altered expression levels of 
genes encoding calcium handling proteins and collagen I. Third, energy source is 
shifted from fatty acid to glucose. Cardiomyocytes use glycolysis to obtain main 
energy for proliferation during embryogenesis but after birth, fatty acid oxidation 
becomes metabolic pathway due to high mitochondrial capacity. This switch is 
broken in pathologic cardiac hypertrophy, in which glucose is rebounced as 
primary energy source (68, 69). Protein synthesis rate is also increased to satisfy 
the requirement of hypertrophied cardiomyocytes. All alterations are the process 
to adapt to increased workloads as compensatory mechanism. However, 
prolonged adaptive responses lead to decompensatory dilated cardiomyopathy, 
and heart failure, which is associated with thin ventricular walls through massive 
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cardiac muscle cell loss. This view is controversial but, a recent finding supports 
that cardiomyocyte loss is sufficient to induce heart failure. It has been shown that 
human heart failure has resulted in increased apoptotic cardiomyocyte death (70, 
71). Genetically enhanced caspase-8 in mouse heart has been shown dilated 
cardiomyopathy with exaggerated apoptosis (72). A well-known apoptotic 
pathway is caspases-dependent and is further stimulated by cytoplasmic release 
of cytochrome C. However, mitochondrial independent cell death pathway is also 
involves in heart failure, which utitlizes Calpain-Calpastatin system. Calpains are 
Ca2+-activated cysteine proteases (73, 74), leading to protein degradation. 
Calpains affect many biologic processes including cell cycle, migration, 
differentiation and apoptosis (73, 75-79). Stress-induced Ca2+ influx in 
cardiomyocytes activates Calpains leading to cleavage of pro-caspase 12. Finally 
activated caspase12 by Calpains facilitate further caspase cascade including 
caspase 9 and 3 (80, 81).  
      Caspase-indenpendet cell death pathway is also emerging and apoptosis 
inducing factor (AIF) is one of key proteins in this pathway. Originally, it has been 
thought that AIF in mitochondrial inner membrane is critical for mitochondrial 
respiratory complex I integrity, representing NADH oxidoreductase and peroxide 
scavenging activities (82-84). N-terminal domain of AIF contains NADH and FAD, 
critical for mitochondrial respiratory function. Interestingly, AIF is also associated 
with caspase-independent cell death. AIF-meidated death function depends on 
increased intracellular Ca2+ concentration that triggers mitochondrial memebrane 
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depoloarization. This leads to Calpain1 activation, resulting in proteolytic 
cleavage. C-terminal domain of AIF is important for integrity and nuclear 
translocation (85). Nuclear AIF has not been studied well but known that it has 
involved in chromosome breakage and chromatin condensation (86-89).  
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Figure I.5. Morphology of cardiomyocytes in cardiac hypertrophy. Distinct 
morphologic alteration of cardiomyocytes is characterized by increased cell size in 
response to various stimuli. Exercise induced physiologic hypertrophy is usually 
not bad, in which resversely cardiomyocytes come back to normal status. 
However, pathologic cardiac hypertrophy easily enters into unrecovered state with 
sarcomere rearrangement, fetal gene reactivation. Concentric hypertrophy is 
caused by relative increase in the width of cardiac mucle cells. On the other 
hands, great increase in the lenghth than in the width causes eccentric hyperophy. 
This type of cell growth leads to dilated cardiomyopathy. Diagram was reproduced 
from Chien et al. (1999) with permission from copyright Massachusetts Medica 
Society.   
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Figure I.6. Cardiac hypertrophy. The heart enlarges cardiac muscle cell size in 
response to stimulus to decrease ventricular wall stress since cardiac muscle 
cells lose their ability of proliferation soon after birth. Cardiac hypertrophy can be 
classified by stimuli. Physiologic hypertrophy is induced by exercise or pregnancy, 
in which ventricular volume is increased by both wall and septum thickness as a 
result of concentric cardiomyocyte growth. Mostly, this is not harmful because it is 
reversed easily upon reduced stress. Thus any pathologic hypertrophic markers 
such as disorganized contractile proteins and upregulated fetal cardiac genes are 
not detected in physiologic hypertrophy. However, concentric cardiomyocyte 
growth by pathologic stimuli makes thick wall and septum, in which left ventricular 
chamber volume is reduced. Sustained and decompensated concentric 
hypertrophy is not helpful any more to heart although initial hypertrophic growth is 
the result of increased workload demand. It finally leads to unreversible dilated 
cardiomyopathy with loss of cardiac mucle cells. Ventricular chamber size and 
volume is increased along with thinner wall and septum thickness. Diagram was 
adopted from Molkentin et al. (2013), permission #3196690309189. 
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Chapter II 
 
Stress-induced SUMO2/3 conjugation of 
Calpain-Calpastatin system reveals  
a critical function  
in myocardial cell death 
 
 
	   24	  
2.1. Introduction 
      Since many transcription factors involving cardiovascular development such 
as Tbx2 (90), GATA4(91), Nkx2.5(92), Mef2 (93) and SRF(94) have been 
modified by SUMOs, most of known functional studies focuse on SUMO1. 
SUMO1-dependent conjugated those transcription factors activate cardiac genes. 
A recent interesting study has first suggested the correlation of SUMO1 with 
heart. The calcium-transporting ATPase, SERCA2a plays a critical role in Ca2+ re-
uptake to maintain cardiac muscle contraction. Impaired Ca2+ re-uptake has been 
caused by altered expression and activity of SERCA, resulting in heart failure 
(95). In this study, novel regulation has been proposed that SERCA2a is modified 
by SUMO1, improving cardiac function through preserving ATPase activity and 
stability (96). Since they have observed that human and animal failured hearts 
revealed decreased SUMO1 protein level, it was concluded that SUMO1 is 
required for normal cardiac contraction. On the same concept, SUMO1 has been 
also suggested as an anti-fibrotic factor. SUMO1 expression has been promoted 
in the patients with systemic sclerosis (SSc) to trigger TGF-β signaling, involving 
fibrosis (97). SUMO1 has been given as a novel therapeutic target for fibrotic 
disease. However, SUMO1 has been also considered as a protective factor. 
SUMO1 has been increased in response to focal cerebral brain ischemia as well 
as overexpressed SUMO1 has been shown to reduce infarction size in brain (98). 
Although active investigation for SUMO1 and disease, especially heart is currently 
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focused, SUMO2/3 is little vailed. One interesting report has been shown that 
SUMO2/3 specific conjugation modulates the chromain modification complex, 
CoREST-LSD1 (56). It is very interesting since cardiac fetal gene reactivation has 
depended on REST (84)(99). After birth, the expression of fetal cardiac genes is 
shut down by REST, recruiting CoREST-LSD1 complex, finally HDAC1 or 2 (85, 
86)(100, 101). HDAC1 and 2 have been involved in regulation of genes encoding 
cardiac specific myofibrillar protein and calcium channels such as T-type calcium 
channel Cav3.2 and troponin I (TnI) (99, 100). Thus abolished HDAC1/2 has 
caused high sensitivity to stress induced cardiac hypertrophy by altered cardiac 
specific gene expression and GSKβ signaling. Those support that there is another 
modulation layer, different from SUMO1 to release repressive REST-CoREST-
LSD1 complex for stress-induced reactivation of fetal cardiac genes in adult. 
Moreover, Calpain2, a calcium dependent protease system component has been 
SUMO2/3-ylated, involving cell migration (102). Increased Calpain1 and 
Calpastatin has been involved in heart disease caused by uncontrolled protein 
degradation (88)(103), suggesting that SUMO2/3 dependent modification of 
Calpain2 might influence the cardiac function.  Further, the first study of SUMO-
dependent PTM with human cardiovascular disease has shown that sumoylation 
defect lamin A mutation is involved in familiar dilated cardiomyopathy (104-106). 
Especially, decreased lamin A function has been related to SUMO2/3 dependent 
modification and resulted in cell death facilitation and abnormal nuclear envelop 
integrity (105). The stress induces high increase in SUMO2/3 conjugation but not 
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in SUMO1 although the function of conjugated SUMO2/3 is little known. SUMO1 
and SUMO2/3 have different specificities to targets although somehow they 
overlappe target proteins. Collectively, although SUMO2/3 has been studied little 
compared with SUMO1, it could play a role to maintain healthy heart state. 
Studies about SUMO2/3 in the heart were undertaken to examine a unique role 
for SUMO2/3 during congenital heart disease.   
2.2. Materials and Methods 
Human heart samples. The explanted human failing hearts were collected during 
transplantation at the St. Luke Episcopal Hospital, Houston, TX. All hearts were 
frozen in liquid nitrogen and stored at -80°C until use. Failing hearts were from 
adults diagnosed with dilated cardiomyopathy (DCM). Normal human hearts used 
as controls were obtained from donors who died from motor-vehicle accidents. All 
studies were performed using left ventricles. 
Angiotensin-II (Ang-II) administration. Animal model was made by the lab. 
Member, Ling Qian as following. 8- to 12-week-old mice were used for either 
sham-operation or Ang-II (AnaSpec Inc.) administration as described (107). 
Anesthetized mice with avertin (240mg/kg, injected intraperitoneally (IP injection) 
were intubated and ventilated for the procedure. Ang-II was delivered by 
implantation of a miniosmotic pump (Alzet, model 1007D) dorsally, containing 
either Ang-II (3mg/kg/d) in 0.9% NaCl.  0.9% NaCl solution alone will be delivered 
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to utilize as control. Hearts were harvested 7 days after Ang-II infusion (108, 109). 
Heart abnormality was evaluated by comparing HW/BW of sacrificed mice.  
Generation of transgenic mice.  The α-MHC-SUMO2 transgene was 
constructed as described (93)(110) under the control of mouse α-MHC promoter 
(provided by Dr. J. Robbins, University of Cincinnati). DNA sequecing was used to 
confirm the orientation of inserted transgene. The pronucleus microinjection of  
transgene construct into the fertilized eggs from FVB mice to generate founder 
(F0) SUMO2 transgenic (SUMO2Tg) mice. Foudners were crossed back with 
C57Bl/6 mice for pure background. Genomic DNA was isolated from tail biopsies 
performed on weaned animals (approximately 3-week old pups) and screened by 
PCR. The expression of transgene in SUMO2Tg mouse hearts was verified by 
Western blot and/or qPCR. Animal work was followed by accordance with IACUC 
approval. 
 
Echocardiography. Mice of interest were anesthetized by inhalation of 1% 
isofluorane and rested on a warm pad during transthoracic measurements of 
cardiac function using two dimensional M-mode of a Vevo 770 in vivo micro-
imaging system (Visual Sonics, Toronto, Canada). The probe contacted with hair-
removed chest to record cardiac function indices. The anlaysis of cardiac function 
and heart dimensions was performed and evaluated under genotype-blinded 
condition. Cardiac functional analysis using echocardiography was performed by 
lab. member, Wei Yu.  
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Histopathology. Mice hearts were dissected and fixed overnight in 4% 
paraformaldehyde (PFA). Hematoxylin and eosin (H&E) or Masson’s trichrome 
staining was performed on heart sections (10 µm) according to standard 
protocols.  
Transmission Electron Microscopy. Left ventricle tissue was fixed in 2% 
paraformaldehyde (PFA) and 3% glutaraldehyde in 0.1M cacodylate buffer, pH7.3 
and prepared according to standard protocol. Electron microscopy was examined 
in a JEM 1010 transmission electron microscope (JEOL, USA, Inc.) at an 
accelerating voltage of 80kV. Digital images were obtained using AMT Imaging 
System (Advanced Microscopy Techniques Corp). This work was done by MD 
Anderson HREM facility. 
RNA Isolation and mRNA quantification. RNA was extracted from age-matched 
WT or SUMO2Tg mouse hearts using Trizol according to the manufacturer’s 
protocol. Reverse transcription reaction was performed using 1 µg total RNA per 
reaction and cloned reverse transcriptase (Invitrogen), followed by qPCR 
(7900HT, Applied Biosystems) using the following gene-specific primers: SUMO-
1: forward, 5’ TCTGACCAGGAGGCAAAACC 3’; reverse, 5’ 
CTAAACCGTCGAGTGACCCC 3’. SUMO-2: forward, 5’ 
GACGAGAAACCCAAGGAAGG 3’; reverse, 5’ CTCCAGTCTGCTGCTGGAAC 3’. 
SUMO-3: forward, 5’ CCAAGGAGGGTGTGAAGACA 3’; reverse, 5’ 
TCAATAGCACAGGTCAGGACA 3’. ANF: forward, 5’ 
GTGTCCAACACAGATCTGATGGAT 3’; reverse, 5’ 
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GCCTAGTCCACTCTGGGCTCCAAT 3’. BNP: forward, 5' 
GGCCAACACCAACCTGTCCAAGTT 3’; reverse, 5' 
TGCAAAGGCTCCAGGTCTGAGGGC 3’. α-MHC: forward, 5’ 
GGAAGAGTGAGCGGCGCATCAAGGA 3’; reverse, 5’ 
TCTGCTGGAGAGGTTATTCCTCGT 3’. β-MHC: forward, 5’ 
GGCCAACACCAACCTGTCCAAGTT 3’; reverse, 5’ 
TGCAAAGGCTCCAGGTCTGAGGGC 3’. skeletal α-actin: forward, 5’ 
AGACACCATGTGCGACGAAGA 3’; reverse, 5’ 
CCGTCCCCAGAATCCAACACGA 3’. GAPDH: forward, 5’ 
ATGTTCCAGTATGACTCCACTCAC 3’; reverse, 5’ 
GAAGACACCAGTAGACTCCACGA 3’. 
Neonatal rat cardiomyocytes culture. Enzymatically dissociated 
cardiomyocytes from 1 to 2-day-old Sprague-Dawley rats were enriched using 
Percoll (GE Healthcare) gradient centrifugation. Isolated cardiomyocytes were 
then plated on collagen-coated dishes (50µg/ml) at a density of 200cells/mm2 and 
maintained in cardiomyocytes culture medium (DMEM supplemented with 10% 
FBS and 2mM of L-glutamine).  
Generation of the recombinant adenoviral vector. Recombinant adenoviral 
vectors were generated by using the AdEasy XL Adenoviral Vector System 
(Stratagene). A DNA fragment containing the full length human SUMO2 and 
mutant human SUMO2 which deletes two guanidine amino acids at C-terminus as 
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well as mouse Calpain2, SUMO2 fused mouse Calpain2 (SUMO-GA-Calpain2) 
and sumoylation site mutated Calpain2 (Calpain2-K390R) were subcloned into 
the pShuttle-IRES-hrGFP1 vector. The entire expression cassettes from the 
resulting vectors were recombined in BJ5183 bacterial strain with serotype 5 first-
generation adenoviral backbone, AdEasy-1 (Stratagene).  These recombinant 
adenoviral backbones were transfected into AD293 cells (Stratagene) to generate 
infectious viral particles. Viral titer was determined by the tissue culture infectious 
dose (TCID50) method (111). Cardiomyocytes were infected with recombinant 
adenoviruses for 2hrs at a multiplicity of infection (M.O.I) of 100 particles/cell and 
incubated for additional 24-48 hrs to ensure transgene expression.  
Annexin-V staining. Annexin V staining was performed using Annexin V Alexa 
Fluor 594 (Invitrogen). Neonatal rat cardiomyocytes on cover slides were added 
by 5µl of the Annexin V Alexa Fluor 594 and incubated for 15 minutes at room 
temperature. Then cells were washed and mounted with Vectashield (Vector 
Laboratory).  
Cardiomyocyte size measurement. WGA-TRITC staining was used on heart 
sections of P5 or P90 WT and SUMO2Tg mice to distinguish sarcolemmal 
membrane. 10-20 randomly selected fields from each individual heart sample was 
used to measure surface areas of cardiomyocytes using Software ImageJ 
(http://rsbweb.nih.gov). The average surface area calculated was normalized by 
WT cardiomyocytes. All analysis was performed under blindness.  
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In vivo Calpain2 activity assay. In vivo Calpain2 activity was analyzed by using 
synthetic substrate t-BOC-Leu-Met-chloromethylaminocoumarin (t-BOC-LM-
CMAC, Invitrogen). HeLa cells were plated at 70-80% confluence in 22mm square 
coverglass (Coring) and grown in complete media for 24hrs. Cells were 
transfected with plasmids encoding the Calpain2, SUMO2 fused Calpain2 
(SUMO-GA-Calpain2) and sumoylation site mutated Calpain2 (Calpain2-K390R) 
in pShuttle-IRES-hrGFP-1. pShuttle-IRES-hrGFP-1 was used as empty vector. 
After two more days incubation, cells were incubated for 30 min in the presence of 
10µM t-BOC-LM-CMAC. Then cells were washed with PBS before covering with a 
glass cover slide. Both GFP and t-BOC-LM-CMAC positive cells were scored for 
analysis. Fluorescence was visualized using a fluorescence microscope (Olympus 
fluorescence microscope). Intensity of fluorescence caused by cleavage of 
synthetic substrate was measured using Image J. Because backgrounds between 
each coverslips slightly varied, background measurements were also taken and 
subtracted. Calpain2 activity was expressed as CTCF (corrected total cell 
fluorescence), which is calculated as follows: integrated density − (area of 
selected cell × mean fluorescence of background readings).  
Immunostaining. HeLa cells were cultured in DMEM containing 10% FBS and 
1% penicillin/streptomycin antibiotics. 70% confluent cells were replated into two 
well Lab-Tek II chamber slide (Nunc) with 4x104 cells density were transfected 
with mouse Calpastatin (mCAST, 0.5ug/well) and SUMO2 fused mCAST 
(SUMO2-mCAST, 0.5ug/well). Transient transfections were performed using 
	   32	  
Lipofectamine 2000 (Invitrogene) according to the manufacturer’s protocol. 
Briefly, Plasmid applied with 0.5µg were mCAST expression vector and SUMO2 
fused mCAST (SUMO2-mCAST) expression vector. Media were changed at next 
day. Cells were maintained additional day. Transfections were done in triplicate. 
HeLa cells were fixed in 3.5% PFA and permeabilized with 0.5% Triton X-100. 
Each transfected construct staining was conducted with anti-V5 antibody (1:200, 
Bethyl Laboratories, Inc.). Cells were sequentially incubated with secondary 
antibodies, Alexa Fluoro® 488 anti-goat antibody (Invitrogen) and then mounted 
with Vectashield with DAPI (Vector Laboratory).  
      To detect DNA synthesis in heart tissues, BrdU was injected intraperitoneally 
into age-matched mice at a dose of 100µg/g body weight. Sixteen hours after 
injection, mouse hearts were isolated, fixed in 4% PFA, dehydrated in increasing 
concentrations of ethanol (up to final of 100%), and sectioned at 5 µm thickeness. 
Paraffin embedded heart sections went further into antigen-unmasking step by 
boiling in 10mM sodium citrate buffer (pH6.8) for 15min. BrdU staining was 
conducted with BrdU in situ detection kit according to the protocol provided by the 
manufacturer (BD Pharmingen). Ki67 or phosphoylated Histone H3 staining was 
performed by using anti-Ki67 antibody (1:200, Santa Cruz) or anti-phopho Histone 
3-Ser10 (1:200, Millipore). Anti-caveolin 3 antibody (1:8000, Santa Cruz) was 
used as a cardiomyocyte marker. Sections were then incubated with the following 
secondary antibodies: anti-rabbit TRITC antibody or anti-mouse FITC antibody 
(Jackson ImmunoResearch). Sections were mounted with Vectashield containing 
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DAPI (Vector Laboratory). BrdU and Ki67 labeling indices were calculated based 
on scores obtained from at least 6 different hearts (3 for each group), with each at 
least 5 fields (adult hearts) randomly selected for evaluation. To analyze the 
apoptosis, ApopTag® Red In situ Apoptosis Detection Kit (Milipore) was applied. 
TUNEL staining followed to the standard protocol provided by the manufacturer. 
Immunoblotting. Mouse hearts were removed and stored at -80°C until use. For 
protein extraction, 100 µg of protein lysates from mouse hearts or 50 µg of 
neonatal rat cardiomyocytes lysates containing overexpressed proteins were 
purified in a cold lysis buffer (50mM Tris-HCl, pH7.4; 0.5% sodium deoxycholate; 
1% NP-40; 150mM MaCl; 1mM EDTA; 1mM DTT; 0.5mM PMSF) containing 
protease inhibitor cocktail (Roche) and presence of 20 mM isopeptidase inhibitor 
N-ethylmaleimide (NEM), which prevents desumoylation of SUMO-conjugated 
substrates. The tissue lysates were solubilized for 20 min on the ice. Then the 
supernatants were separated by centrifugation at 13,000 rpm for 15 min at 4°C. 
The supernatants were used for immunoblot analyses and immunoprecipitations. 
For immunoprecipitation, protein lysates from frozen mouse hearts were 
prepared. 400 µg of total protein was diluted to a final concentration of 0.4 mg/ml 
in lysis buffer. 4 µg of bead-conjugated anti-SUMO-2/3 antibody (Santa Cruz) was 
applied to the sample and incubated for 2 hours at 4°C on a rotary platform. The 
beads were subsequently pelleted by centrifugation, washed five times with lysis 
buffer. These protein lysates were subsequently subjected to 4-12% NuPAGE, 
transferred to PVDF membrane, detected with the desired  
	   34	  
antibody, which was then visualized with chemiluminescence.  
Statistics. Numbers of mice for each group used in each experiment are 
indicated in the Figure legends.  2-tailed student’s t-test was used to determine 
statistical significance between groups and error bars represent means± s.e.m.   
P value < 0.05 was considered statistically significant and P<0.005 as highly 
significant.  
2.3 Results 
Enhanced expression of SUMO2 causes cardiomyopathy. Human failing 
hearts made elevated SUMO2/3 conjugation compared to normal hearts (Figure 
II.1.a). This result was also observed in the artificial cardiac stress induced animal 
model in which cardiac stress was introduced through angiotensin-II (Ang-II) 
administration (Figure II.1.b). To determine whether SUMO2 is sufficient to induce 
pathologic hearts, heart specific SUMO2 transgenic mice under the control of α-
MHC promoter directing cardiomyocyte-specific expression of transgene were 
generated. Several independent Tg lines were established based on immunoblot 
analysis, and we chose lines with high (9606 or 9610 lines), medium (9592 line) 
and low (9608 line) expression for characterization. Figure II.2.a represented 
SUMO2 protein level of 9592 line. The change of SUMO2/3 conjugated protein 
level (HMW) from human diseased and SUMO2 Tg (9592 line) hearts was 
comparable (Figure II.2.b). Thus heart specific SUMO2 Tg can be used to study 
the function of SUMO2/3 in the pathologic condition.   
	   35	  
 
 
 
 
 
 
 
 
Figure II.1. Endogeneous SUMO2/3 protein levels in diseased heart. a, 
SUMO2/3 conjugation in human heart tissues (n=3 per non-failing heart (cont), 
n=6 per heart failure (HF, n=3 for non-ischemic heart failure (NIS-HF), n=3 for 
ischemic heart failure (IS-HF)) are represented. b, Representative immunoblot for 
SUMO2/3 in experimental animal model which is Ang-II (3mg/kg/d, 1wk) 
stimulated heart disease model. GAPDH, glyceraldehyde 3-phosphate 
dehydrogenase, HMW, high molecular weight group. 
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Figure II.2. Generation of cardiac specific transgenic mice with increased 
SUMO2 expression and conjugation.  a, Heart specific SUMO2 transgenic mice 
were generated using α-MHC promoter. Transgene, SUMO2 was constructed 
and modified to result in high conjugation activity contained SUMO2 by expose of 
diglycine motif at C-termini. Immunoblot analysis of SUMO2/3 protein in the 
mouse heart confirmed that both conjugated and free SUMO2/3 was highly 
increased in the Tg. GAPDH was used as a loading control. WT, wild type 
littermate, SUMO2 Tg, heart specific SUMO2 Tg, HMW, high molecular weight 
SUMO2 conjugates. b, Quantification of HMW from immunoblot analysis between 
human and Tg mouse was done using an image process program (ImageJ). Error 
bars represent mean ± SEM. (**P<0.005 vs cont for human, *P<0.05 vs WT for 
mouse, n=5 for human, n=3 for mouse/group)  
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SUMO2 overexpression caused cardiac remodeling. Elevated SUMO2 
expression in murine hearts revealed enlarged hearts at P80 (Figure II.3.a). 
Cardiac function was assessed by echocardiography in SUMO2 Tg at P80. Heart 
specific SUMO2 Tg showed significant reduction in contractility as indicated by a 
reduced EF, FS and increased HW/BW ratio (Figure II.3.b). Fetal cardiac genes, 
such as atrial natriuretic factor (ANF), b-type natriuretic protein (BNP), β-myosin 
heavy chain (β-MHC) and skeletal actin (SK-Act) re-expressed during cardiac 
stress were assessed by qPCR. Those stress marker genes were upregulated, 
but adult form of myosin heavy chain (α-MHC) was downregulated (Figure II.4). 
These results indicate that elevated SUMO2 expression in murine hearts causes 
cardiac stress. To address cardiomyopathy induced by SUMO2 overexpression, 
we analyzed size of cardiomyocyte by weat germ agglutinin (WGA) staining at the 
same age of Figure II.4 (Figure II.5.a). Image J quantification of cardiomyocyte 
cross sectional size of SUMO2 Tg was normalized by one of WT, indicating 
significantly large myocyte from SUMO2 Tg (Figure II.5.b). α-MHC promoter 
SUMO2 Tg exhibited marked cardiac hypertrophy with enlarged heart, 
upregulated fetal cardiac genes, increased cardiac cell size and apparent fibrosis 
(blue) (Figure II.5.c). Some of Tg died suddenly at one week of age, in which the 
level of transgene expression was high such as 9606 or 9610 lines. Those Tgs 
represented smaller body size but enlarged heart, indicating high HW/BW ration 
(Figure III.6.a, b, e). Notably 
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Figure II.3. Cardiac defects caused by cardiac overexpression of SUMO2. a, 
Gross morphological change of hearts from WT and Tg at P80. b, Cardiac 
function was measured through echocardiography. Two-month-old α-MHC-
SUMO2 Tg and their control littermates were analyzed (n=3 for each group). 
Graphs represented a decrease EF, FS and an increase LV mass, which 
indicating hypertrophied hearts. Left ventricle weight was normalized by body 
weight for WT and Tg (two months of age). EF, ejectional fraction. FS, fractional 
shortening. Error bars indicate SEM. (*P<0.05, **P<0.001 vs WT) 
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Figure II.4. SUMO2 overexpression in the heart develops reactivation of fetal 
cardiac genes. Reactivation of fetal cardiac genes was determined in 1year-old 
α-MHC-SUMO2 Tg and WT mice (n=3 for each group). Total heart RNA was 
isolated and prepared for cDNA. Fetal cardiac genes involved in cardiac stress 
were analyzed. Expression levels were normalized by GAPDH. Error bar indicates 
mean±SEM. (*P<0.05, **P<0.0005 vs WT) 
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Figure II.5.  Abnormal cardiac remodeling in SUMO2 Tg.  3-month-old Tg and 
WT littermates were stained. n=3 for each group. a, b, Wheat germ agglutinin 
(WGA) staining was applied to measure the cardiomyocyte size. Quantification of 
cardiomyocyte size from WGA positive heart section by Image J indicated 
increased cardiomyocyte size in α-MHC-SUMO2 Tg (b). Bar, 100µm. Error bars 
indicate the SEM. (**P<0.001 vs WT) c, Masson’s Trichrome staining 
demonstrated fibrosis (blue) was apparently enhanced in cardiac SUMO2 Tg 
compared to WT. Bar, 200µm. 
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ventricular dilation was observed in Tgs. It suggests sudden death is caused by 
dilated cardiomyopathy. Although the suddenly dead Tg revealed dilated 
ventricular wall, cardiomyocyte cross sectional size was significantly increased 
(Figure II.6.c, d), supporting hypertrophic response was common in enhanced 
SUMO2 expressed hearts. To investigate the basic mechanism for dilation, 
TUNEL staining was applied. An increase in apoptotic cell death was prominent 
around one week of age Tgs (Figure II.7.a,b). Moreover, transmission electron 
microscopy from the same aged Tgs showed sarcomere rearrangement and 
disorganized mitochondria (Figure II.7.c). 
Aberrant cardiomyocyte apoptosis in SUMO2 Tg hearts. To test further if 
increased cell death is the primary cause of cardiomyopathy in SUMO2 Tg hearts, 
TUNEL staining was performed in SUMO2 mutant hearts when HW/BW ration 
was not different compare to WT (Figure II.8.c). Even if cardiac stress indicator 
such as HW/BW ratio was not evident, an aberrantly prominent increase of 
apoptosis was also observed in SUMO2 Tg hearts at P4 (Figure II.8.a,b).  
      To evaluate whether increased cell death was caused by SUMO2, AdSUMO2-
GG (constitutive active SUMO2 expressing recombinant adenovirus) was 
generated. Adenoviral infection was controlled as MOI=100 condition, resulting in 
infection of more than 90% of cultured primary neonatal rat cardiomyocytes 
(NRCMs). At 36hrs after infection, NRCMs were stained with Annexin-V to see 
early event of cell death. In normal condition, phosphatidylserine (PS) is located 
on the cytoplasmic surface of the cell membrane; however, in apoptotic cells, PS 
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Figure II.6. Abnormal cardiac growth in SUMO2 Tg hearts. Heart specific 
SUMO2 Tg revealed smaller body size (a) whereas, enlarged heart size (b) 
around one week old. The enlarged hearts from SUMO2 Tg developed dilated 
cardiomyopathy with sudden death. Dramatically severe harm phenotype 
representing SUMO2 Tg expressed higher transgene. c, WGA staining showed 
increased the cardiomyocyte size in α-MHC-SUMO2 Tg around one week old 
(n=3 for each group). Bar, 50µm. d, Cardiomyocyte size was measured using 
Image J, indicating hypertrophic growth was also occurred. Error bars indicate the 
SEM (**P<0.0001 vs WT). e, HW/BW ratio (±SEM, mg/g) of WT and SUMO2 Tg 
mice were determined around one week old. Heart index was significantly 
changed in SUMO2 Tg hearts. 
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Figure II.7. Abnormal cardiac cell death in SUMO2 Tg hearts. 
Immunohistochemistry of WT and Tg mouse hearts around one week old. (n=3 for 
each group) a, TUNEL staining showed highly increased apoptosis in α-MHC-
SUMO2 Tg. TUNEL positive cells were represented as red dots. Cardiomyocyte 
was chosen through Cav3 (green) staining. Nuclear counter staining was done 
using DAPI (blue). Bar, 200µm. b, Only TUNEL-positive and Cav3 positive cells 
were scored at least five randomly selected fields. Error bars indicate the SEM 
(**P<0.005 vs WT). c, TEM image showed disarrayed myofibrils and irregular 
mitochondria in SUMO2 Tg. Bar indicates 500nm. 
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Figure II.8. Early onset of cell death in SUMO2 Tg hearts. 
Immunohistochemistry of WT and Tg mouse hearts at P4. (n=3 for each group) a, 
TUNEL staining showed increased apoptosis in α-MHC-SUMO2 Tg at P4. TUNEL 
positive cells were stained as red dots. Cav3 (green) was used as the 
cardiomyocyte specific marker. Nuclear counter staining was done using DAPI 
(blue). Bar, 200µm. b, Only TUNEL-positive and Cav3 positive cells were counted 
in at least five randomly selected fields. Error bars indicate the SEM (**P<0.005 
vs WT). c, HW/BW ratio (±SEM, mg/g) of WT and SUMO2 Tg mice were 
determined at P4. Although heart index at P4 was not changed, apoptotic cell 
death was significantly increased in SUMO2 Tg hearts. 
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is translocated from the inner to the outer plasma membrane. Annexin-V has the 
high affinity to PS. Thus it can be used to verify the cell death event. Constitutive 
active SUMO2 containing adenovirus infection significantly induced cell death. In 
contrast, this result was totally diminished under SUMO2 conjugation activity dead 
mutant by deleting two glycines at c-termini (AdSUMO2-ΔGG) (Figure II.9). Taken 
together, we conclude that SUMO2 is sufficient for cardiac cell death.  
Calpain2 is modified by SUMO2 in the heart. As the calcium-dependent 
protease, Calpain2 is modified by SUMO and is involved in cell death (102, 112). 
In addition, sumoylation of Calpain2 results in the activation of its enzymatic 
reaction (102). Heart specific overexpression of Calpain2 causes reduced cardiac 
function including LVESD (left ventricular end-systolic dimension), FS (fractional 
shortening) just one week after induction (103). There are mainly three different 
isotypes of Calpain in the heart : Calpain1, 2 and 3 (113). Calpain1 and 2 are 
expressed ubiquitously but Calpain3 is found only in skeletal muscle. We 
examined sumo-dependent modification in vitro for all three isoforms. Only 
Calpain2 showed SUMO dependent modification. Thus SUMO-conjugation of 
Calpain2 in murine hearts was tested under the enhanced expression of SUMO2. 
Using immunoblot and immunoprecipitation assay, SUMO2 specific modification 
of Calpain2 was observed in the SUMO2 Tg (Figure II.10.a, b). Because human 
heart failure promoted SUMO2/3 conjugation (Figure II.1.a), we also examined 
Calpain2 modification in the human hearts. Multiple additional bands of Calpain2  
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Figure II.9. Cardiac specific cell death on cultured neonatal rat 
cardiomyocytes (NRCMs). a, Immunostaining for Annexin V (red) on NRCMs 
after 36hrs after active SUMO2 (AdSUMO2-GG), diglycine deleted SUMO2 
(AdSUMO2-ΔGG) or empty (AdGFP) adenovirus infection at MOI=100. 
Overexpression of active SUMO2 in NRCMs resulted in increased Annexin V 
positive cells. It indicated that cell death was facilitated. Bar, 50µm. b, 
Quantification of apoptosis in NRCMs. Annexin V positive cells were scored at 
least 100 cells from tree independent experiments and averaged. (**P<0.001 vs 
AdGFP) 
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Figure II.10. Calpain2 is modified by SUMO2/3 and is involved in pathologic 
hearts. a, b, WT and α-MHC-SUMO2 Tg heart tissue homogenates were 
assessed for Calpain2 in immunoblot (IB) (a) or immunoprecipitation (IP) analysis 
(b). Enhanced expression of SUMO2 caused Calpain2 modification as shown a. 
Those additional bands were confirmed as sumoylation, especially by SUOMO2 
(b). c, d, Human failing heart also exhibited additional upper band of Calpain2 in 
IB (c). Those modified bands were also proved as SUMO2/3-dependent 
conjugation of Calpain2 in IP (d). SUMO2/3ylated Calpain2 was clearly increased 
in dilated cardiomyopathic human hearts. IP was performed using agarose-
conjugated anti-SUMO2/3 antibody for pulldown, followed by immunoblot using 
anti-Calpain2 antibody.  
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in failing human hearts were determined as SUMO2-specific (Figure II.10.c,d). 
These data suggest that increase in SUMOylation of Calpain2 is the conserved 
observation in diseased heart both in murine and human.   
      Calpain-2 is involved in caspase-independent cell death pathway along with 
ER stress (114). To examine whether the SUMO2-conjugated Calpain2 
associates directly with apoptosis, we used adenoviral mediated gene delivery 
system in NRCMs.  Through Annexin-V staining assay, a 2.5-fold increase was 
observed in the Calpain2 (AdCalpain2) overexpressed NRCMs respectively. 
Interestingly, this increase was accelerated by SUMO2 fused Calpain-2 
(AdSUMO2-GA-Calpain2) introduction. The number of Annexin-V positive NRCM 
were abrogated by forced expression of SUMO2 conjugation site mutated 
Calpain2 (AdCalpain2-K390R) (Figure II.11), suggesting that SUMO2 dependent 
modification of Calpain2 induces cardiac muscle death directly.    
      We examined that SUMO2-dependent modification influences activity of 
Calpain2 alternatevely using synthetic substrate, t-BOC. Calpain2 expressing 
HeLa cells showed 1.8-fold increased activity in HeLa cells (Figure II.12). 
Interestingly, even higher enzymatic activity was observed in SUMO2 fused 
Calpain2 (AdSUMO2-GA-Calpain2) expressing cells whereas, mutant Calpain2 
deleting the site for SUMO2 conjugation (Calpain2-K390R) revealed decreased 
enzymatic activity. This result indicates that SUMO2-conjugation facilitates 
catalytic activity of Calpain2. Of note, SUMO2 conjugation mutant Calpain2  
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Figure II.11. Calpain2 induced cell death is enhanced by SUMO2 
conjugation. a, Adenoviral delivery of Calpain2 induced cell death on NRCMs 
based on Annexin V staining. SUMO2 conjugation promoted cardiomyocyte death 
(AdSUMO2-GA-Calpain2). This effect was diminished on sumoylation site 
mutated Calpain2 overexpressed NRCMs (AdCalpain2K390R). Bar, 50µm. b, 
Quantitative analysis of Annexin V labeling. The number of double positive 
(Annexin V/GFP) NRCMs was chosen from at least 100 cells on randomly 
selected field. Data were collected 3 independent experiments. All adenoviral 
constructs were delivered at MOI=100. (**P<0.001 vs AdGFP, # P<0.005 vs 
AdCalpain2) 
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Figure II.12. The proteolytic activity of Calpain2 is enhanced by SUMO2 
conjugation. HeLa cells were transfected by cDNA encoding each construct, 
Calpain2, SUMO2 fused Calpain2 (SUMO2-GA-Calpain2) and mutant Calpain2 
(Calpain2-K390R). Trasfected cells were selected by GFP expression. Synthetic 
substrate, t-BOC-LM-CMAC was visualized cleavage-dependently by Calpain. 
Cells were scored by double positive signals of GFP and t-BOC-LM-CMAC. 
SUMO2 enhanced proteolytic activity of Calpain2. However this increase was 
attenuated by mutant Calpain2, to which SUMO2 was not conjugated. Data were 
collected independent experiments. (**P<0.0005 vs GFP, # P<0.005 vs Calpain2) 
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(Calpain2-K390R) still showed significantly high proteolytic activity compared with 
control (GFP only). It might be explained by several reasons. Since the synthetic 
substrate, t-BOC-LM-CMAC responds to both Calpain1 and Calpain2, it would be 
hindered. Also, the endogenous Calpain1 would be affected by activated 
Calpain2 since this analysis was performed without any Calpain1 inhibitor.  
Calpastatin is modified by SUMO2 in pathologic hearts. Homeostatic protein 
turn-over including contractile machinery is critical to maintain the beating ability 
in the heart. Calpain-dependent proteolytic pathway is proposed as one of system 
especially, in the skeletal muscle (75, 115, 116). The Calpastatin, an endogenous 
inhibitor prevents Calpains proteolytic activation by binding (80). Unbalanced 
expression of Calpastatin resulted in Calpainopathy including dilated chamber, 
reactivation of fetal genes and decreased cardiac contractility with distorted 
myofibrillar architecture (103). We hypothesized that increased SUMO2 protein 
level hits not only Calpain2 but also its binding partner, Calpastatin under stress 
condition. To identify Calpastatin protein level in the diseased heart model, an 
immunoblot analysis was performed in SUMO2 Tg and failured human hearts. 
Both diseased hearts represented additional bands above Calpastatin band (90 
kDa) respectively (Figure II.13. a, c). Immunoprecipitation analysis was used to 
confirm that Calpastatin was at least partially conjugated by SUMO2 in the 
pathologic hearts (Figure II.13. b, d).  
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Figure II.13. Calpastatin is modified by SUMO2/3 and is involved in 
pathologic hearts. a, b, WT and heart specific SUMO2 Tg heart tissue 
homogenates were used for calpastastin in immunoblot (IB) (a) or 
immunoprecipitation (IP) analysis (b). Increase in SUMO2 level resulted in 
Calpastatin modification as shown a. Those additional slow migration bands were 
turned as SUMO-conjugated one, especially by SUOMO2 (b). c, d, Human failing 
heart also showed additional upper band of Calpastatin in IB (c). Those modified 
bands were also proved as SUMO2/3-dependent modified Calpastatin in IP (d). 
SUMO2/3ylated Calpastatin was visibly increased in dilated cardiomyopathic 
human hearts. The agarose-conjugated anti-SUMO2/3 antibody was utilized for 
pulldown, followed by immunoblot using anti-Calpastatin antibody. NS, none 
specific.
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Calpastatin is a novel SUMO2 target. Protein kinase A (PKA) and protein 
kinase C (PKC) have been reported to modify and to modulate Calpastatin activity 
(117, 118). Here we showed that pathologic hearts stimulated SUMO-dependent 
modification of Calpastatin (Figure II.13). To define the molecular basis, in vitro 
system was applied along with transfection method. Although SUMO1 was even 
aggressively conjugated, both SUMO1 and SUMO2 were responsible for 
Calpastatin modification (Figure II.14.a). To verify that those slowly migrating 
bands were SUMO-dependent, conjugation defective SUMO (SUMO-∆GG-flag), 
which served as the binding platform was deleted. Indeed, cotransfection of 
mutant SUMO (SUMO-∆GG-flag) and Calpastatin (CAST-V5) into HeLa cells 
abolished upper defined but slower migrating band of WT SUMO (SUMO-flag) 
(Figure II.14.b). Taken together, these results suggest that SUMOylation is a 
novel post-translational modification of Calpastatin. Next we asked how SUMO-
dependent modification affects Calpastatin. SUMOylation has been reported 
essential to stabilize HIF1α during hypoxia (119) and critical subcellular 
localization of target such as Drp-1 (59), leading to the hypothesis that SUMO- 
dependent conjugation of Calpastatin is critical for its stability, cellular localization 
and interaction ability to Calpain2.  
	   59	  
 
 
 
 
 
 
 
 
 
 
 
 
Figure II.14. Calpastatin is modified by SUMO. a. cDNAs coding Calpastatin 
(CAST) with V5 tag and SUMO1 or SUMO2 in which flag was conjugated were 
cotransfected into HeLa cells. Ni-NTA pull down showed that Calpastatin is 
sensitive to both SUMO1 and SUMO2 although SUMO1 dependent conjugation 
was active than SUMO2 dependent one. b. Modified upper bands detected in a 
were confirmed as SUMO-dependent conjugated Calpastatin. Mutant SUMO 
cDNA coding SUMO without diglycine (ΔGG) acting as immatured SUMO, fused 
Calpastatin cotransfected HeLa cells completely lost SUMO-conjugated upper 
band. HMW, high molecular weight globally modified SUMO targets. 
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To evaluate the ability of SUMO2 conjugation on Calpastatin stability, a protein 
half-life analysis was performed using cycloheximide (CHX). Because CHX blocks 
protein synthesis, it is useful to study already synthesized protein degradation 
rate. Clear and slow migrating Calpastatin band indicating SUMO conjugated 
Calpastatin was attenuated upon cotransfection of Calpastatin (CAST-V5) along 
with SUMO (SUMO-Flag) in the CHX treatment, as indicated in Figure II.15.a. 
Notably, free Calpastatin protein level was not affected even if protein synthesis 
was inhibited for 12 hrs by CHX, in accordance in the strong stability of 
Calpastatin against the heat. This result was reproducible in the presence of 
SUMO fused Calpastatin (SUMO-CAST-V5) whereas, not in the unSUMOylated 
Calpastatin (CAST-V5) expressed HeLa cells (Figure II.15.b). These results 
support our hypothesis that SUMO-conjugation makes the calpastastin unstable. 
Calpastatin itself is also controlled by several proteases such as caspases, 
Calpains, which is critical for proteolytic activity of Calpains (74, 80, 114, 120). 
Together, next prompted question was which protease is involved in SUMO-
dependent degradatin of Calpastatin. SUMO fused Calpastatin expressing vector 
was transfected into HeLa cells with each protease inhibitors including Calpain1, 
2, cathepsins and caspases under blocking protein synthesis. SUMO fused 
Calpastatin was quite resistant to pan caspase inhibitor treatment (Figure II.15.c), 
demonstrating that SUMO conjutaed Calpastatin is sensitive to caspase mediated 
degradation.  
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Figure II.15. Sumoylation promotes Calpastatin degradation. a, b. SUMO 
conjugated Calpastatin (a) or SUMO fused Calpastatin (b) showed unstability. In 
block of newly synthesized protein through cycloheximide treatment, SUMOylated 
Calpastatin was degraded time-dependently compared to free calpastsatin. c. 
Among known Calpastatin degrading enzymes, SUMO-conjugation made 
Calpastatin sensitive to caspase, leading to release from Calpain2.   
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It is quite consistent with the concept that caspase mediated degradation of 
Calpastatin contributes to apoptosis although activated Calpains also tear down 
Calpastatin (114). 
      To establish whether SUMOylation promotes subcellular translocation of 
Calpastatin, free Calpastatin (CAST-V5) or SUMO2 fused Calpastatin (SUMO2-
CAST-V5) was overexpressed in HeLa Cells. Capastatin with or without SUMO2 
was visualized through immunofluorescence staining using anti-V5 Ab and 
counted as aggregated or cytoplasmic distribution (Figure II.16), indicating that 
Calpastatin changes its subcellular localization dependent on SUMO2 conjugation. 
Recent studies demonstrated that phosphorylation regulates subcellular 
localization of Calpastatin and that cAMP mediated dephosphorylated Calpastatin 
enters aggregated inactive distribution (117). It is consistent with our finding 
(Figure II.16), demonstrating that it is possible that increased aggregate pattern of 
SUMO2 fused Calpastatin is inactive. All data support that the inhibitory role of 
Calpastatin against Calpain2 is modulated by SUMO2-dependent modification.  
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Figure II.16. SUMOylation changes intracellular Calpastatin localization. a, 
CAST or SUMO2 fused CAST in HeLa cells were visualized by immunostaining 
through V5 tag (green fluorescence). DAPI staining (blue fluorescence) was used 
as nuclear counter staining. Diffused pattern (left panel) in cytoplasm of CAST is 
totally changed under SUMO2 conjugation (right panel). Bar indicates 50µm. b, 
Bar graph indicates the percentage of cells with each localization. Data were 
collected from 4 independent experiments. (**P<0.001). 
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2.4 Discussion  
Dynamic SUMOylation in congestive heart disease. SUMO conjugation is one 
of growing reversible posttranslational modification (PTM), involving many 
different biologic processes such as cell death, transcription, cell cycle, protein 
stability etc. Although its role in cardiac development is well established especially 
with SUMO1, very little is known about the role of SUMO2/3 particularly in 
congestive heart disease. Here we have identified that SUMO2/3 is upregulated 
in human and experimental animal failing hearts. It is correlated that SUMO2/3 is 
more sensitive to environmental stress (47). This elevated SUMO2/3 level is not 
protective but detrimental for cardiac function based on heart specific SUMO2 Tg. 
Increased global SUMO2/3 conjugation level (high molecular weight, HMW) is 
even critical for modulation of their targets to affect on cardiac function. Since one 
of SUMO2 Tg lines showed no HMW level change in spite of increased free 
SUMO2/3, which did not reveal any cardiac defects under normal condition 
whereas Ang-II stimulation caused significantly increased global SUMO2/3 
conjugation and sudden death (Figure II.17).  Consistently, SUMO E3 ligase, 
protein inhibitor of activated STAT 2 (PIAS2) was up-regulated in human failing 
hearts, indicating that SUMO conjugation is facilitated actively in stressed hearts 
(Figure II.18). It suggests that SUMO2/3 conjugation is more important for cardiac 
remodeling responding to stress. Alternatively, the contribution of SUMO1 
conjugation to heart is very controversial. 
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Figure II.17. Stress inducing SUMO2/3 conjugation in the heart. a. 
Homogenates from WT and SUMO2 Tg hearts with or without Ang-II 
administration were applied to immunoblot using anti SUMO2/3 antibody. Ang-II 
administration induced SUMO2/3 conjugation in heart specific SUMO2 Tg, in 
which global SUMO2/3 conjugation was not observed. Interestingly, elevated 
SUMO2 conjugation level correlated with mortality rate (b). Exaggeratedly 
increased SUMO2 conjugation would result in fatal phenotypes. 
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Figure II. 18. Pathologic human hearts induced active SUMO conjugation. 
Human hearts from normal or failing were prepared to obtain protein lysates. 
Immunoblot analysis was applied for PIAS2 protein level. Human Failing hearts 
and experimental animal model revealed active conjugation of SUMO2/3 (Figure 
II.1). SUMO E3 ligase, PIAS2 was also significantly enhanced in human failing 
hearts. Since SUMO E3 ligase accelerates SUMO conjugation in the SUMO 
pathway, it supports that increased global SUMO2/3 conjugation from human 
failing heart is caused by not only SUMO2/3 but also active conjugation pathway. 
Normal, healthy heart; NIS-HF, none ischemic heart failure (dilated 
cardiomyopathy) ; IS-HF, ischemic heart failure.   
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Ca2+ reuptake-involving ATPase, SERCA2a has been modified by SUMO1. Both 
SUMO1 and SUMO1 dependent PTM of SERCA2a have been decreased during 
heart failure (96). However the others reported that increase in SUMO1 has been 
induced in pathologic hearts in purpose of protection (98, 121) or pathological 
progress (97).  Our approach has identified that global SUMO1 conjugation level 
is increased or unchanged in human failing hearts and Ang-II stimulated murine 
hearts (Figure II.19). Thus increased SUMO1 conjugation is more related to 
protective function.  
SUMO2 inducing cell death.  The prominent outcome upon SUMO2 
overexpression in the neonatal rat cardiomyocytes (NRCMs) was apoptotic cell 
death, indicating that primary effect of SUMO2 enhancement in the hearts is the 
myocyte death. This detrimental effect was abolished by conjugation activity dead 
SUMO2 mutant (AdSUMO2-ΔGG) that ablates diglycine residues on SUMO2. In 
accordance, clinically increased cardiomyocyte death was reported as a clear 
phenomenon in human heart failure (70, 71). Several animal studies also 
supported that heart failure was induced sufficiently by heart specific apoptosis 
(72, 122, 123). Apparently, SUMO2/3 can be sufficient to control cell death in 
cardiac muscle tissues.  
     Cardiac cell death caused by upregulated SUMO2 is possibly associated with 
Ca2+ -dependent cysteine protease, Calpain 2 based on our observation 
indicating its increased SUMO2 specific sumoylation in SUMO2 Tg and human 
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Figure II.19. Stress induced abnormal hearts elevated SUMO1-dependent 
modification. Immunoblot analysis was performed by utilizing whole heart 
homogenates to check SUMO1 alteration. Stress induced overload by Ang-II 
treatment showed similar pattern of SUMO1 compared to SUMO2/3 conjugation 
(Figure II.1). Stress induced pathologic condition triggers SUMO1 conjugation 
also. However, SUMO1 conjugation seems the protective effect than deteriorative 
one.
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failing hearts (Figure II.10). Calpain has been known to be involved in 
mitochondria independent cell death pathway (80). Moreover, Calpain 2 has been 
identified to be regulated by SUMO2-dependent modification (102). Here we 
confirmed that cardiac muscle cells are also affected by enhanced SUMO2 
conjugated Calpain2, especially apoptotic cell death. It is intriguing that the more 
Ca2+-sensitive Calpain, Calpain1, has not shown a SUMO dependent modification 
in our trial. Only Calpain2 showed SUMO2 dependent modification, resulting in 
enhanced proteolytic activity. The little effect of Calpain2 overexpression for 
cardiac remodeling in a previous study (103) might result from no consideration of 
SUMO2 in their study. Interestingly we have found that its endogenous inhibitor, 
Calpastatin is also modified by SUMO2 specifically in human failing heart and 
animal model. SUMO2 dependent modification modulates the stability and 
subcellular localization of Calpastatin. It supports our idea that enhanced SUMO2 
protein level hits both Calpain2 and Calpastatin, resulting in the enhancement of 
enzymatic activity of Calpain2 and weakening Calpastatin’s inhibitory function by 
altered stability and localization within cell. Although Calpastatin has been 
reported that its subcellular localization is changed by phosphorylation (117, 118, 
124), little is known about how phosphorylated Calpastatin affects on association 
with Calpain. Moreover, under normal Ca2+ condition, there is no evidence to 
explain how Calpain2 and Calpastatin regulate each other. Here our study 
strongly supports that enhanced global SUMO2/3 conjugation at least, in partial 
involves in Calpain2-Calpastatin system to induce mitochondria-independent 
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apoptosis pathway by activating Calpain2 but by releasing its inhibitory partner, 
Calpastatin. However still remaining question is the relationship between 
phosphorylation and SUMOylation for control of the same system.  
Cardiomyocyte survival and SUMO2. Along with increased cell death, 
cardiomyocyte proliferation has been also decreased remarkably in SUMO2 Tg. 
Very recently, AMP-activated protein kinase (AMPK) has been discovered as a 
novel SUMO2 target (125). Moreover, AMPK has been activated specifically by 
SUMO2 conjugation to AMPKβ2. Activated AMPK by reduced mitochondrial ATP 
production negatively regulates cell cycle checkpoint in Drosophila (126, 127), 
indicating mitochondrial complex mediated regulation of cell proliferation. Since 
SUMO2-dependently modified AMPKβ2 has resulted in increased activity, it 
provides obvious possibility that decreased cardiomyocyte proliferation in heart 
specific SUMO2 Tg is due to activated AMPK via enhanced SUMO2 conjugation. 
Furthermore, human familiar mutation in AMPK mimic animal model, PRKAG2-
N488I Tg under α-MHC promoter has developed hypertrophic heart with elevated 
AMPK activity (128). Collectively, these emphasize that the important role of 
SUMO2 dependent modification in cell proliferation contributes to cardiomyocyte 
survival during cardiac reprogramming.  
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Chapter III.  
 
SENP5-dependent deSUMOylation pathway  
in dilated cardiomyopathy 
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3.1. Introduction 
       SENP1 representing preferences to all SUMO isoforms, has shown that its 
knock-out (SENP1 KO) mouse model reveals the sensitivity to hypoxia, 
suggesting SENP1 involves in HIF1α stability (119). In another instance of even 
preferences for SUMO1 and 2/3, SENP2 knock-out (SENP2 KO) mice have 
developed congenital heart disease with growth retardation (129). The primary 
cause of embryonic or neonatal death in SENP2 KO mice is atrial septum defects 
(ASD) and/or ventricular septum defects (VSD) induced by significantly decreased 
cell proliferation. Those studies suggest that each SENP might involve in a 
distinct biologic pathway despite their similar target preferences for SUMO 
isoforms.  
      SENP3 has been involved in protein turnover via stable interaction with CHIP 
(co-chaperone/ubiquitin ligase carboxyl terminus of Hsc 70-interacting protein) 
and Hsp90 (heat shock protein 90) (130). SENP7 has regulated epithelial to 
mesenchymal transition by SUMO2/3-dependnet modification of heterochromatin 
protein 1α (HP1α) (131, 132). In that study, larger metastatic lesions in lung were 
formed upon SENP7 silencing (131). Both SENP3 and SENP7 prefer SUMO2/3 
rather than SUMO1 as their substrates but they have different enzymatic activity: 
SENP3 tends to mediate deconjugation more whereas SENP7 mediates SUMO 
chain editing (133). Collectively, those suggest that each SENP has a specific role 
	   73	  
to control biologic phenomena as variable manners including substrate specificity, 
different subcellular occupancy and distinct enzymatic activity and so on.  
      SENP5 favoring SUMO2/3-deconjugation has revealed the distinct subellular 
pattern to control cell proliferation and mitochondrial dynamics by shuttling 
between nucleolus and mitochondria (36, 37, 57). During mitotic cell division, 
SENP5 has escaped from nucleus to move to mitochondria (36). Mitochondria-
staying SENP5 could involve in mitochondrial fragmentation to distribute 
mitochondria evenly into daughter cells. Additionaly, SENP5 has been shown to 
be required for cell proliferation (57). Mitochondrial fission protein containing 
GTPase activity, Drp-1 has been reported to be deconjugated as SENP5-
dependent manner although its SUMOylation seems SUMO1-dependent manner 
(59). Ectopic expression of SENP5 induced mitochondrial fission with active cell 
death. More interestingly, Drp-1 mutation by ENU has result in dilated 
cardiomyopathy with low mitochondrial function in the mouse (134). It is the first 
report to link SENP5 with disease, particularly heart disease. Additionally, heart is 
very energy demanding organ to maintain contraction continuously, thus it habors 
mitochondria abundantly. Given its potential biological activity and unexplored 
physiological significance, this study could provide valuable evidence to explain 
the possible role of SENP5 for cardiac disease development.  
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3.2. Material and Methods 
Human heart samples.  Failing human left ventricular samples obtained from St 
Luke Episcopal Hospital were removed during cardiac transplantation. Failing 
hearts were from adults diagnosed with dilated cardiomyopathy (DCM). Normal, 
non-failing adult human heart samples were collected from motor-vehicle 
accidents dead donors. The left ventricular samples were used for studies. 
Animal studies. The α-MHC-SENP5 transgene was constructed as described 
(93)(110) under the control of mouse α-MHC promoter (provided by Dr. J. 
Robbins, University of Cincinnati). DNA sequecing was used to confirm the 
orientation of inserted transgene. The pronucleus microinjection of transgene 
construct into the fertilized eggs from FVB mice to generate founder (F0) SENP5 
transgenic (SENP5Tg) mice. Foudners were crossed back with C57Bl/6 mice for 
pure background. Genomic DNA was isolated from tail biopsies performed on 
weaned animals (approximately 3-week old pups) and screened by PCR. The 
expression of transgene in SUMO2Tg mouse hearts was verified by Western blot 
and/or qPCR. Animal work was followed by accordance with IACUC approval. 
Echocardiography. Mice of interest were anesthetized by inhalation of 1% 
isofluorane and rested on a warm pad during transthoracic measurements of 
cardiac function using two dimensional M-mode of a Vevo 770 in vivo micro-
imaging system (Visual Sonics, Toronto, Canada). The probe contacted with hair-
removed chest to record cardiac function indices. The anlaysis of cardiac function 
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and heart dimensions was performed and evaluated under genotype-blinded 
condition. Lab. member, Wei Yu helped animal cardiac functionality analysis 
through echocardiography. 
Transmission Electron Microscopy. Left ventricle tissue was fixed in 2% 
paraformaldehyde (PFA) and 3% glutaraldehyde in 0.1M cacodylate buffer, pH7.3 
and prepared according to standard protocol. Electron microscopy was examined 
in a JEM 1010 transmission electron microscope (JEOL, USA, Inc.) at an 
accelerating voltage of 80kV. Digital images were obtained using AMT Imaging 
System (Advanced Microscopy Techniques Corp). The process for EM was done 
by MD Anderson HREM facility and Texas Heart Institute pathology core.  
Mitochondrial enzyme activity assay. Mice hearts mitochondrial enzyme 
activities were determined spectrophotometrically as described previously with 
slight modification (135, 136). Mitochondria were isolated from mice cardiac 
ventricular tissues by homogenization in lysis buffer (100mM potassium 
phosphate buffer, 1mM EDTA, 1mM β-mercaptoethanol (pH7.4), protease 
inhibitor and 10mM NEM). Tissue extracts were incubated for 60min at 4°C to 
ensure complete enzyme extraction. 0.1% Triton X-100 was added to 
permeabilize cell membranes. The mitochondrial fraction was separated by 
further differential centrifugation. Before assay, homogenates or mitochondrial 
fraction were thawed and frozen three times. All mitochondrial enzyme activities 
were measured using quartz cuvette. Complex I activity was determined by 
monitoring the reduction of ferricyanide at 420nm. Homogenates were added to 
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reaction buffer (120mM Triethanolamine (pH7.8), 0.5mM ferricyanide, 5mM 
rotenone) to start the reaction at 30°C for 2min. The NADH-dependent 
ferricyanide reduction was measured. Complex II activity was measured as the 
decrease rate of 2,6-dichlorophenolidophenol (DCPIP) when coupled to the 
complex II catalyzed reduction of decylubiquinone (DB) at 600 or 750nm. 
Homogenates (80µg) or mitochondria (30µg) were added to reaction reagents 
(0.1M potassium phosphate buffer (pH7.4), 20mM succinate. After this mixture 
was incubated at 30°C for 5min, antimycin A (2µg), rotenone (2µg), KCN (2mM), 
DCPIP (50µM) were added. The reaction was started by DB (50µM) addition. The 
change of absorbance was monitored during 5min reaction. Complex IV activity 
represents the activity of cytochrome c oxidase by monitoring the oxidation of 
reduced cytochrome c at 550nm. Protein extracts (80µg) or mitochondria (30µg) 
were added to reaction reagents (20mM potassium phosphate (pH7.4) and 20mM 
succinate). 10µM cytochrome c was added to initiate the reaction at 30°C for 1-
2min. Citrate synthase activity was examined by monitoring the absorbance at 
412nm using especially unsonicated mitochondrial proteins. The frozen cardiac 
tissues were homogenized in 20% (wt/vol) lysis buffer (20mM HEPES, 10mM 
EDTA, 1mM EGTA, 1mM DTT, 5mM MgCl2, 0.1% Triton X-100). Extracts were 
incubated at 4°C for 60min to ensure complete enzyme extraction. Heart 
homogenates reacted with 0.05mM oxaloacetate in reaction buffer containing 
20mM HEPES, 1mM EGTA, 220mM sucrose, 40mM KCl, 0.1mM DTNB and 
0.1mM Acetyl-CoA (pH7.4) at RT. The reaction mixture excluding oxaloacetate 
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was used as reference. All measured activities were normalized by WT record 
and expressed as percentile.   
Histology. Hearts were removed and fixed overnight in 4% paraformaldehyde 
(PFA), embedded in paraffin. Hematoxylin and eosin (H&E) or Masson’s 
trichrome staining was performed on heart sections (10 µm) according to 
standard protocols. Ca2+ deposits from paraffin sections (5 µm) were assessed 
using von Kossa staining according to the manufacturer’s protocol (Diagnostic 
BioSystems Inc.) with nuclear fast red staining as counter staining.  
Immunohistochemistry. To detect DNA synthesis in mice hearts, BrdU was 
injected intraperitoneally into pregnant female mice bearing embryos or postnatal 
pups at a dose of 100µg/g body weight. Sixteen hours after injection, hearts were 
collected, fixed in 4% PFA, dehydrated in increasing concentrations of ethanol (up 
to final of 100%), and sectioned with 5 µm thickeness. BrdU staining was 
conducted with BrdU in situ Detection Kit according to the manufacturer’s protocol 
(BD Pharmingen). For staining, commonly antigen retrieval was performed by 
boiling slides in 10 mM sodium citrate (pH 6.0, 15 min) followed by blocking in 
10% normal goat serum (NGS) for 1 h at room temperature (RT). Ki67 or 
phosphoylated Histone H3 staining was performed with anti-Ki67 antibody (1:200, 
Santa Cruz) or anti-phopho Histone 3-Ser10 (1:200, Millipore). Anti-caveolin 3 
antibody (1:8000, Santa Cruz) was used as a cardiomyocyte marker. Sections 
were then incubated with the following secondary antibodies: anti-rabbit TRITC 
antibody or anti-mouse FITC antibody (Jackson ImmunoResearch). Sections 
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were mounted with Vectashield including DAPI (Vector Laboratory). BrdU and 
Ki67 labeling indices were calculated based on scores obtained from 6 different 
embryonic or adult hearts (at least 3 for each group), with each at least 100 cells 
(embryonic hearts) or 5 fields (adult hearts) randomly selected for evaluation. 
Assessment of TUNEL was conducted using ApopTag® Red In situ Apoptosis 
Detection Kit (Milipore) based on the standard protocol provided by the 
manufacturer. 
Generation of the recombinant adenoviruses. Recombinant adenoviral vectors 
were generated by using the AdEasy XL Adenoviral Vector System (Stratagene). 
A DNA fragment containing the full length human SENP5 which was the gift of 
Dr.Ed Yeh, The University of Texas MD Anderson Cancer Center and mutant 
human SENP5 which does not have any enzymatic activity coding sequences 
were subcloned into the pShuttle-IRES-hrGFP1 vector. The entire expression 
cassettes from the resulting vectors were recombined in BJ5183 bacterial strain 
with serotype 5 first-generation adenoviral backbone, AdEasy-1 (Stratagene).  
These recombinant adenoviral backbones were transfected into AD293 cells 
(Stratagene) to generate infectious viral particles. Viral titer was determined by 
the tissue culture infectious dose (TCID50) method (111). Cardiomyocytes were 
infected with recombinant adenoviruses for 2hrs at a multiplicity of infection 
(M.O.I) of 100 particles/cell and incubated for additional 24-48 hrs to ensure 
transgene expression.  
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Neonatal rat ventricular cardiomyocytes culture. Neonatal rat cardiomyocytes 
were prepared as described (137). Breifly, primary cultures of cardiac myocytes 
from 1- to 3-day- old Sprague-Dawley rats were prepared. Ventricles were 
enzymatically dissociated, and the cells were collected for only cardiomyocytes 
using Percoll (GE Healthcare) gradients. Cells were plated onto the collagen-
coated cover slips at a density of 200cells/mm2 and maintained in cardiomyocytes 
culture medium (DMEM supplemented with 10% FBS and 2mM of L-glutamine).  
Immunofluorescence staining. Cardiomyocytes grown on collagen-coated 
cover slips or two well Lab-Tek II chamber slide (Nunc) were fixed in 3.5% PFA 
and permeabilized with 0.5% Triton X-100. Then slips were incubated with 10% 
normal goat serum for blocking for 1hr at room temperature. Sequentially the cells 
were treated with anti-caspase 3 antibody (1:200, Santa Cruz) and TRITC-
conjugated goat anti-rabbit IgG (Jackson ImmunoResearch) and then mounted 
with Vectashield containing DAPI (Vector Laboratory). Annexin V staining was 
performed using Annexin V Alexa Fluor 594 (Invitrogen). Neonatal rat 
cardiomyocytes on Lab-Tek II chamber slides were added by 5ul of the Annexin V 
Alexa Fluor 594 and incubated for 15 minutes at room temperature. Then cells 
were washed and mounted with Vectashield containing DAPI (Vector Laboratory). 
AIF (hAIF) point mutations, K85R (conversion of lysine 85 to arginine) and K442R 
(conversion of lysine 442 to arginine) were done using Stratagene mutagenesis 
kit based on manufacturere’s protocol. Mutations were verified by sequencing. 
Transient transfections were performed on HeLa cells through Lipofectamine 
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2000 (Invitrogen). Briefly, plasmids applied with 0.5µg were point mutated hAIFs ( 
AIF-K85R, AIF-K442R) containing p3xFLAG-CMV-10 expression vectors (Sigma-
Aldrich). Media were changed to complete media at next day. Cells were 
maintained additional day. Transfections were done in triplicate. HeLa cells were 
fixed in 3.5% PFA and permeabilized with 0.5% Triton X-100. After blocking with 
10% NGS, HeLa cells were treated with anti -Flag antibody (1:1000, Invitrogen) 
and subsequently FITC-conjugated goat anti-mouse IgG (Jackson 
ImmunoResearch) and then mounted with Vectashield containing DAPI (Vector 
Laboratory). 
Immunoblotting & Immunoprecipitation. Briefly, 100 µg of protein lysates from 
mouse hearts or 50 µg of NRCM containing overexpressed proteins were purified 
in the presence of 25 mM isopeptidase inhibitor N-ethylmaleimide (NEM), which 
prevents substrate desumoylation. These protein lysates were subsequently 
runned to 4-12% NuPAGE, transferred to PVDF membrane, detected with the 
desired antibody, which was then visualized with chemiluminescence.  
 For immunoprecipitation, protein lysates from frozen mouse hearts were 
prepared. 400 µg of total protein was diluted to a final concentration of 0.4 mg/ml 
in lysis buffer. 5 µg of bead-conjugated anti-SUMO-2/3 antibody (Santa Cruz) was 
applied to the sample and incubated for 2 hours at 4°C on a rotary platform. The 
beads were subsequently pelleted by centrifugation, washed five times with lysis 
buffer. Specifically bound proteins were eluted by 4x SDS sample buffer, 
subjected to SDS- PAGE, and visualized by autoradiography.  
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Subcellular Fractionation. Appropriate amount of mice hearts was minced in 5 
volumes of mitochondrial isolation buffer (220mM mannitol, 68mM sucrose, 80mM 
KCl, 0.5mM EGTA, 2mM MgAc2, 10mM HEPES (pH7.4), protease inhibitor 
cocktail and 20mM NEM) as describe (59). Heart tissues were ruptured and 
homogenized under speed of middle stroke to fast stroke at least fourtimes. The 
lysates were centrifuged at 500×g for 5min at 4°C. The resuspended pellet in the 
mitochondrial isolation buffer was homogenized again and separated twice more. 
Collected supernatants were pooled and centrifuged at 1000×g for 5min at 4°C. 
Result pellets were collected as the nuclear fraction. Cleared supernatants were 
centrifuged at 12,000×g for 15min at 4°C. Mitochondrial pellets were washed and 
resuspended in mitochondrial isolation buffer. Remained supernatants were 
saved as cytosolic fraction. Samples were further resuspended in SDS sample 
buffer and probed with anti-SENP5 antibody (Abcam), anti -Drp-1 antibody (BD 
Transduction Lab.) and anti-TOM 20 antibody (Santa Cruz) for immunoblotting 
analaysis. For immunoprecipitation, only mitochondrial fractions were used. 70µg 
of mitochondrial fraction was diluted in mitochondrial isolation buffer and an 
appropriate amount (5ug) of bead-conjugated anti-SUMO-2/3 antibody was added 
to the sample and incubated for 2 hours at 4°C.  The beads were subsequently 
pelleted by centrifugation, washed five times with mitochondrial isolation buffer. 
Bound proteins were eluted by 4x SDS sample buffer, subjected to SDS- PAGE, 
and visualized by autoradiography.  
RNA isolation and mRNA quantification. Total RNA was isolated from age- 
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matched snap-frozen hearts using Trizol reagent (Invitrogen). cDNA was 
prepared by cloned reverse transcriptase (Invitrogen). Cardiac stress indicating 
gene expression was determined by qPCR (7900HT, Applied Biosystems) using 
FastStart SYBR Green master (ROX)(Roche). mRNA levels were normalized by 
the housekeeping gene, GAPDH.  
Statistics. Numbers of mice for each group used in each experiment are 
indicated in the Figure legends.  2-tailed student’s t-test was used to determine 
statistical significance between groups and error bars represent means± s.e.m.   
P value < 0.05 was considered statistically significant and P<0.01 as highly 
significant.  
3.3 Results 
SENP5 is upregulated during human heart failure. Sumoylation process is 
very dynamic and is known to involve in cardiovascular development. Although 
enhanced expression of SENP2 results in congenital heart disease (129), very 
little is known about other SUMO pathway components during heart disease. To 
identify the SENP5 expression level, immunoblot analysis was performed using 
human hearts. Human heart failure revealed highly elevated SENP5 protein level 
(Figure III.1.a). However the function of elevated SENP5 protein level in human 
heart failure is not clear. Thus human SENP5 transgene was applied to express 
under the α-MHC promoter (SENP5 Tg). Three lines of Tg, #2723, #2737 and 
#2739 showed forced expression of SENP5 in hearts (Figure III.1.b). We also 
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confirmed transgene expression through Southern blot, RT-PCR and qPCR (data 
not shown). Those supported SENP5 is overexpressed under the α-MHC 
promoter. SENP5 transgene expression level was compared with diseased hearts 
from human based on immunoblot analysis (Figure III.1.a, b). Cardiac specific 
SENP5 Tg represented comparably and similarly high protein level to human 
Cardiac specific SENP5 Tg represented comparably and similarly high protein 
level to human SENP5 in diseased hearts (Figure III.1.c). It suggested that 
cardiac specific SENP5 Tg could be used as a good animal model to study the 
function of increased SENP5 protein level in diseased human hearts. Further, 
SENP5 Tg revealed SUMO1 conjugation was not changed (Figure III.1.d) but 
SUMO2/3 conjugation was decreased (Figure III.1.e), indicating SUMO2/3 
specificity of SENP5 Tg mice.   
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Figure III.1. Increased SENP5 expression level in human heart failure. a, 
SENP5 in human heart tissues (n=3 per non-failing heart (cont), n=3 for non-
ischemic heart failure (NIS-HF), n=3 for ischemic heart failure (IS-HF)) are 
represented. b, Cardiac specific (α-MHC promoter) SENP5 Tg were generated. 
Proteins were prepared from ventricles of Tg at 2-month-old age for Immonoblot 
analysis using α-SENP5 antibody. GAPDH was used as a loading control. c, 
Comparison of SENP5 increased level from Immunoblot analysis (a, b) by 
quantification using ImageJ. Error bars represent mean ± SEM. (**P<0.05 vs cont 
for human, vs WT for mouse, n=5-7 for human, n=3 for mouse/group) d, e, Sumo-
conjugation was admitted using Immunoblot analysis on hearts from b. Increased 
unconjugated SUMO2/3 (arrow) resulted from SENP5 transgene (d). SUMO-1 
conjugation was not affected by SENP5 overexpression (e).  
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SENP5 Tg mice developed cardiac pathology. To address whether elevated 
SENP5 is detrimental to the heart, 2723 line of heart specific SENP5 Tg was 
selected. This Tgs grew without any apparent abnormalities including behavior, 
fertility for several months. However α-MHC promoter bearing SENP5 Tg showed 
sudden death starting 8 days after birth, which was most severe impairment. Two-
month-old hearts from SENP5 Tg were enlarged (approximately 1.5 times 
increase compared to WT) and had significantly decreased cardiac function 
(Figure III.2) with extensive fibrosis (Figure III.3.b). α-MHC promoter carrying 
SENP5 Tg revealed the remarkable reduction in cardiac contractility at diastole 
and systole, a significant increase in left ventricular internal diameter at diastole 
(LVIDd) and at systole (LVIDs), as well as reduced ejectional fraction (EF) along 
with impaired fractional shortening (FS) (Figure II.2.b). Another consequence of 
the cardiac stress response is upregulation of cardiac fetal genes. As shown in 
Figure III.3.a, reactivation of markers, atrial natriuretic peptide (ANF), brain 
natriuretic peptide (BNP), β-myosin heave chain (β-MHC) were notably observed 
in SENP5 overexpressed murine hearts (Figure III.3.a). Expression of connective 
tissue growth factor (CTGF) and collagen type I (Col1) were also induced (data 
not shown), correlating with Masson’s trichrome staining (Figure III.3.b). 
Interestingly, no difference in LV posterior wall thickness in diastole (LVPWd) 
indicated that SENP5 Tg hearts were not hypertrophic. This was confirmed by 
histological sections stained by H&E of Tgs which were dead suddenly around 
P10 (Figure III.4.a).
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Figure III.2. Cardiac defects resulting from cardiac overexpression of 
SENP5. a,  Whole-mount pictures of the hearts at two-month-old. b, Analysis of 
cardiac function of Tg and WT littermates (n=5-6) by echocardiography.  LVIDd: 
left ventricular internal diameter at end-diastole; LVIDs: left ventricular internal 
diameter at end-systole; LVPWd: left ventricle posterior wall thickness at end-
diastole; EF: ejectional fraction; FS: fractional shortening; LV mass/BW: left 
ventricle mass-to body wight ratio (* P<0.05, **P<0.005 vs WT).  
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Figure III.3. Cardiac defects resulting from cardiac overexpression of 
SENP5. a, Total heart RNA was isolated from 2-month-old mice and prepared for 
the cDNA. Indicated markers of cardiac stress were determined using qPCR. 
mRNA levels are expressed as relative value to GAPDH. Error bars indicate SEM.  
(*P<0.05, **P<0.005 vs WT). b, sections stained with Masson’s Trichrome to 
address fibrosis. Bar, 10µm. Enhanced expression of SENP5 in heart resulted in 
intensive fibrosis (blue).  
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Sudden dead SENP5 Tg displayed dilated cardiomyopathy with thinner 
ventricular wall and dilated chamber volume accompanying large thrombi in 
ventricles (Figure III.4). All together, these results suggest that elevated SENP5 
protein level observed in human failing hearts is involved in progress of heart 
disease, especially, dilated congestive heart failure.  
Abberant cardiomyocyte proliferation and death upon forced expression of 
SENP5. To investigate the basis of obviously reduced wall thickness, which is one 
of characters of dilated cardiomyopathy, cell proliferation was analyzed by Ki67 
staining. SENP5 overexpressing animals selected at P8 showed a 3.5-fold 
decrease in cell proliferation compared with wild type (WT) (data not shown). 
Consistently, cell death was also clearly increased at the same stage (data not 
shown). It was expected because the aged Tg already developed sudden death 
with dilated cardiomyopathy. Thus we selected 5-day-old time window at which 
heart specific SENP5 Tg did not represent any cardiac defects such as HW/BW 
ratio (Figure III.6.c). Unexpectedly, this time point (P5) already displayed 
decreased cardiomyocyte proliferation based on Ki67 staining (Figure III.5). Since 
Ki67 staining did not distinguish DNA synthesis, S-phase and mitotic cell division, 
to gain further insight, DNA synthesis was first evaluated through BrdU staining. 
The number of BrdU positive cardiac cells, integrating into DNA during S-phase 
was significantly decreased. Next, staining for phospho Histone H3, a marker of 
mitotic cell division was applied. The number of phospho Histon H3 (pH3) positive  
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Figure III.4. Abnormal hearts developed in cardiac SENP5 Tg. a, Cardiac 
specific SENP5 Tg died suddenly around P10. Whole-mount pictures of the 
hearts from WT and cardiac specific SENP5 Tg mice at P8 are shown in the top 
panel. Bottom panels show histological sections stained with H&E. SENP5 Tg 
develops big heart with thin chamber wall in ventricle. Bar, 200µm (bottom panel). 
b, Heart weight (mg) to body weight (g)(HW/BW) ratio in mice of a. SENP5  Tg 
reveals increased heart index. Error bar indicates SEM. (**P<0.001 vs WT) 
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Figure III.5. Aberrant cardiomyocyte proliferation in SENP5 Tg. 
Immunohistochemistry for cell proliferation markers at P5. a, Phospho- histone H3 
(red) and DAPI (blue) staining show increased cell proliferation, especially mitotic 
cardiomyocytes. Statistical analysis in b represents the scores of at least 5 
randomly selected fields per section. c, Ki67 staining represents decreased cell 
proliferation in SENP5 Tg hearts. d, statistical results represent average scores of 
200 cells per section. Quantification of each positive staining is done at least three 
different samples. Caveolin-3 (Cav3, green) was used as a cardiomyocyte 
specific marker.  Bar, 50µm. (**P<0.0005 vs WT)
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Figure III.6. Abnormally increase in cell death in SENP5 Tg hearts. a, Double-
immunofluorescence analysis of TUNEL(red) and Cav3(green) showed increased 
apoptosis in Tg at P5. Bar represents 100µm. b, The number of double positive 
(TUNEL+:Cav3+) cells were counted  from at least three randomly selected field. 
Error bar represents mean ± SEM. (**P<0.005 vs WT, n=4) One of cardiac 
disease indicator, HW/BW ratio was not changed in SENP5 Tg at the same age of 
increased cell death (c). DATA were collected from 72 animals from 6 litters.
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cardiomyocytes were remarkably reduced at SENP5 Tgs. These results suggest 
that Increased SENP5 protein level affects cardiomyoctye proliferation.  
      SUMO-dependent modification is known to involve in apoptotic cell death (44), 
indicating possibly desumoylation enzyme, SENP5 protein level might influence 
cell death. Also, dilated ventricle from SENP5 Tg might be possibly caused by cell 
death. Therefore TUNEL assay was applied to murine hearts at P5 (Figure III.6). 
TUNEL positive dead cardiomyocytes were dramatically facilitated by heart 
specific SENP5 Tg compared to WT, in spite of no evidence in heart stress index. 
Collectively, thinning ventricular wall of SENP5 Tg was caused by increased cell 
death and decreased cardiomyocyte division.  
 
Increased cardiomyocyte death is SENP5-dependent. This in vivo observation 
provided a valuable clue that overexpression of transgene, SENP5 in murine 
hearts impacts on cell survival. Thus we wanted to examine whether significantly 
increased apoptosis is the direct result of SENP5 overexpression especially in the 
hearts. To address this, adenovirus carrying wild type SENP5 (AdSENP5-wt) and 
desumoyation activity dead SENP5 (AdSENP5-mut) were generated and 
transduced in neonatal rat ventricular cardiomyocytes (NRCMs). Annexin-V is a 
calcium-dependent phospholipid binding protein and is used to detect cell death. 
During cell death, inner plasma membrane located phosphatidylserine (PS) is 
exposed to the external environment. Due to high affinity to PS, main 
phospholipid in the plasma membrane, Annexin-V is useful for cell death  
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analysis. Transiently overexpressed SENP5 in primary cardiomyocyte culture 
substantially increased cell death (Figure III.7). However it was totally abrogated 
upon introduction of deconjugation enzymatic activity mutated SENP5. 
Quantification of Annexin-V positive cardiomyocytes was consistent with 
immunostating analysis (Figure III.7.b).  
      Additional cell death properties including cytoplasmic release of cytochome C 
and nuclear accumulation of active caspase-3 were determined to confirm. 
Cytoplasmic fraction from both NRCMs and murine hearts revealed cytochrome C 
release upon SENP5 overexpression (Figure III.8.a). Nuclear translocation of 
caspase-3 was prominent in AdSENP5-wt transduced NRCMs but not in 
AdSENP5-mut transduced ones (Figure III.8.b), suggesting that enhanced SENP5 
expression in the heart is specific and sufficient to induce cardiomyocyte death.  
The mitochondrial fission protein, Drp-1 is sensitive to SENP5. Recent 
reports indicate that mitochondria also harbor SUMO pathway components, 
suggesting that potential SUMO targets could be located in mitochondria (17, 36, 
37). Among them, we tested mitochondrial fission protein, Drp-1, which was 
initially reported as a SENP5 target in COS cells (37). In addition, its ENU 
mutagenesis study showed the same cardiac structural defect, dilated 
cardiomyopathy of heart specific SENP5 Tg (134). Cardiac Drp-1 was examined 
in carefully isolated subcellular fractions including nuclear, cytosolic and 
mitochondrial fraction from murine hearts. Most of Drp-1 was detected as a free 
form with remarkably reduced level of SUMO conjugated form in SENP5  
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Figure III.7. Cardiomyocyte death is induced directly by SENP5 
overexpression. a, Immunostaining for Annexin V (red) on NRCMs after 24 or 
36hrs after wild type SENP5 (AdSENP5-wt), enzymatic activity dead mutant 
SENP5 (AdSENP5-mut) or empty (AdGFP) adenovirus infection at MOI=100. 
Enhanced expression of SENP5 in NRCMs resulted in increased Annexin V 
positive cells. Bar, 50µm. b, Annexin V positive NRCMs were scored and 
normalized by GFP positive NRCMs at least 100 cells from tree independent 
experiments and averaged. (**P<0.001 vs AdGFP) 
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Figure III.8. SENP5 facilitates cell death in NRCMs. a, Cytoplasmic release of 
cytochrome c. Cytosolic fraction from NRCM or mouse heart was applied to 
analyze by immunoblot. Cytosolic accumulation of cytochrome c was observed in 
both in vitro (left panel) and in vivo (right panel) SENP5 overexpression condition. 
b, Nuclear translocation of caspase-3 in SENP5 overexpressed NRCMs. 
Cytoplasmic remained caspase-3 in normal condition (AdGFP) was translocated 
into the nucleus under SENP5 overexpression (AdSENP5-wt). Accumulated 
caspase-3 induced by SENP5 overexpression was diminished by desumoylation 
activity dead SENP5 (AdSENP5-mut). Bar indicates 50µm.  
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overexpressed hearts (Figure III.9.a). Interestingly, this pattern was prominent at 
the mitochondrial fraction. SENP5 was also observed in the mitochondrial 
fraction, which correlated with increased desumoylated drp-1 in the mitochondrial 
fraction. Mitochondrial Drp-1 was sensitively desumoylated by SENP5 based on 
immunoprecipitation analysis. Particularly, SENP5 overexpression caused 
SUMO2/3-conjugated Drp-1 to be desumoylated (Figure III.9.b).  
      Since SUMOylated Drp-1 facilitates mitochondrial fission (30)(37), it was 
examined that mitochondrial dynamics is influenced by desumoylation of Drp-1 
upon SENP5 especially in the heart. Mitochondrial size was measured from TEM 
images. Mitochondria were remarkably enlarged in heart specific SENP5 Tg mice 
(Figure III.10). Interestingly, SENP5 Tg already developed enlarged mitochondria 
although heart index including HW/BW ratio was not changed. These results 
suggested that SENP5 overexpression might involve in mitochondria. Thus our 
next question was whether mitochondrial enzymatic activities were affected by 
SENP5 overexpression at the same time point of Figure III.10. As complex II 
consists of only nucleus-encoded subunits, therefore measurement of complex II 
activity can be useful for comparison with activities of the other complexes. In 
addition, citrate synthase is a sensitive indicator for mitochondrial activity, 
because decreased level of citrate synthase indicates that mitochondrial function 
was declined. In accordance with results from mitochondria size and apoptosis 
analysis of SENP5 Tg, reduced mitochondrial enzymatic activity already started at 
P5 (Figure III.11). Moreover, heart specific SENP5 enhancement influcenced not 
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Figure III.9. Increased desumoylation of mitochondrial protein in cardiac 
specific SENP5 Tg heart. a, SENP5 target candidates were examined on 
desumoylation through Western blot analysis. Mitochondrial fission protein, 
Dynamin- related protein (Drp-1) was desumoylated in Tg heart mitochondrial 
extracts. Mitochondrial fraction showed decreased sumoylated Drp-1 but 
increased free Drp-1. Arrows indicate unconjugated Drp-1 (bottom) and  
sumolyated Drp-1(upper). TOM20 was used to verify mitochondrial fractionation. . 
(N, Nuclear fraction; C, cytosolic fraction; M, mitochondrial fraction) b, 
Sumoylated Drp-1 was confirmed by immunoprecipitation (IP) analysis. 
Mitochondrial fraction from WT and SENP5 Tg hearts were used for IP with anti 
Drp-1 antibody and for IB with anti SUMO2/3 antibody. 
	   99	  
 
 
 
 
 
 
 
Figure III.10. Overexpression of SENP5 causes enlarged mitochondria. a, 
Electron microscopy images were collected from WT and SENP5 Tg at P5, which 
showed increased cell death but no change in HW/BW ratio (Figure III.5). Bar 
indicates 500nm. b, Mitochondrial size were measured by ImageJ and statistically 
analyzed. Size was measured from at least four randomly selected regions 
(20,000x magnification) and normalized by WT. Error bar represents mean ±SEM. 
(**P<0.0001 vs WT, n=4 for each group). Data revealed mitochondria were enlarged 
by SENP5 overexpression.  
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Figure III.11. Mitochondrial dysfunction in cardiac specific SENP5 Tg heart. 
The activity of mitochondrial respiratory complex II, IV and citrate synthase were 
determined from WT and α-MHC-SENP5 Tg at P5 spectrophotometrically. 
SENP5 overexpression in heart resulted in decreased mitochondrial respiratory 
complex activity. Error bar indicates SEM. (*P<0.05 vs WT, n=20 for each group). 
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only the nuclear DNA encoding mitochondrial complex but also the mtDNA 
encoding complexes, suggesting that decreased mitochondrial respiratory chain 
complex activities were primarily due to SENP5 overexpression.  
 Necrotic mitochondrial defects. Unexpectedly, we found severely degenerative 
mitochondrial structures in TEM of SENP5 Tg hearts at P10 (Figure III.12.a-b’). 
SENP5 Tg hearts from P10 showed enlarged mitochondria and prominently loss 
of cristae (Figure III.12.b’), indicating necrotic mitochondrial structures. At this 
time point, α-MHC promoter carrying SENP5 Tg died suddenly accompanied with 
dilated ventricles. Also cardiac defects such as high HW/BW ratio, remarkable 
increase of cell death and declined respiratory chain activities (data not shown) at 
the same time point led to necrotic cell death in SENP5 Tgs. Thus we analyzed 
Ca2+ deposition via von Kossa staining to address whether detrimental 
mitochondrial structure is caused by necrosis. Remarkable Ca2+ deposition was 
observed starting from P10 but more prominent at P15, corresponding with 
cardiomyocyte necrosis (Figure III.12.c-d). It supports that necrosis causes 
sudden death with severely dilated ventricle starting from one week after birth 
upon elevated SENP5 level. 
AIF subcellular localization depends on SENP5. Necrosis is known to occur 
passively. However recent works provide evidence that some necrosis was 
programmed (138-141), especially mitochondrial-dependent necrosis (142, 143). 
Mitochondrial structure, activity and dynamics defects were not enough to explain 
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Figure III.12. Mitochondrial defects caused by SENP5 overexpression. a, b, 
Transmission electron micrographs of WT and Tg mice at P10 showed  that the 
majority of mitochondria were damaged, swollen and their cristae in disarray. a’, 
b’, higher magnification of a, b represents clear abnormal patterns of cristae in 
Tg. M, mitochondrion c, d, Histological assessment of Ca2+ deposition 
representing as brown dots in the ventricle by von Kossa staining. Bar, 500nm (a-
b’), 50µm (c,d).  
	   103	  
that the SENP5 Tg induced necrosis. Here we focused on apoptosis inducing 
factor (AIF) as a new target of SENP5 to mediate both apoptosis and necrosis. 
Initially, it has been known that nuclear synthesized AIF moves into mitochondria 
by its mitochondria leading sequence (MLS), at which it involves in apoptotic cell 
death. However recent rising evidences supported that mitochondrial localized 
AIF can be translocated reversely into the nucleus where it is involved in necrosis. 
Several candidate sites (ψKXE) for SUMO conjugation were found within human 
AIF (hAIF) through bioinformatic analysis. To examine whether hAIF is modified 
SUMO-dependently, HeLa cells were co-transfected by vectors expressing 
human AIF (hAIF) with/without SUMO contained vector or with/without SENP5 
carrying vector. It was determined that hAIF was showing clear and slow migrated 
bands corresponding to the SUMO-conjugated form. However, this modulation 
was diminished by desumoylation enzyme, SENP5 (data not shown). Based on 
this observation, we hypothesized that SENP dependent desumoylated AIF is 
released from mitochondria and moves to nucleus to induce necrosis. In 
accordance with the results of in vitro SUMO assay, nuclear localized AIF was 
increased in heart specific SENP5 Tg compared with WT (Figure III.13.a). To 
verify this different subcellular localization of AIF carefully, immunostaining using 
anti-AIF Ab was performed under acute SENP5 overexpression through 
adenovirus in NRCMs. Endogenous AIF was detected in the cytoplasm whereas, 
enhanced SENP5 expression induced endogenous AIF translocation into the 
nucleus in NRCMs (Figure III.13.b). However, nuclear translocated AIF was  
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Figure III.13. Myocardial AIF translocation in cardiac overexpression of 
SENP5. a, Nuclear AIF level was detected by immunoblot analysis from WT and 
α-MHC-SENP5 Tg hearts. Histone 3 specific antibody was applied to verify 
nuclear fraction. N, nuclear extract. b, Nuclear accumulation of AIF is SENP5 
dependent. The redistribution of AIF (red) into the nuclei was explained by the 
overlap of AIF with nuclear staining accessed by DAPI (blue). Nuclear 
translocation of AIF induced by SENP5 was reduced under desymoylation activity 
mutated SENP5 (AdSENP5-mut) overexpressed NRCMs. Bar, 20µm. c, SUMO-
conjugation site mutated AIF (AIF-K58R) was observed in nucleus in HeLa cells. 
Bar, 50µm.
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reduced by enzymatic activity dead mutated SENP5 (AdSENP5-mut) (Figure 
III.13.b), indicating nuclear translocation of AIF from mitochondria is influenced by 
SENP5 directly. As an alternative way to test this hypothesis, one of SUMO site 
candidates within hAIF was mutated to block its SUMOylation and then its 
expression vector was tranasfected into the HeLa cells. Although only one 
candidate (K58R) was examined, AIF-K58R was prominently observed in nucleus 
(Figure III.13.c), indicating SUMO-dependent modulation is critical to determine its 
subcelular localization.  Collectively, these data suggest that SENP5 is sufficient 
and necessary to induce different subcellular localization of AIF.  
 
3.4. Discussion 
 
The detrimental role of SENP5 in congestive heart disease. SENP5 is known 
to express during embryogenesis and its expression declines after birth despite 
ubiquitous expression in the body. It has been shown that SENP5 is upregulated 
upon diabetes and oral squamous cell carcinoma (60). However, until now, there 
is little attention focused on SENP5 in the heart, especially congestive heart 
disease. Enhanced SENP2 expression in the murine hearts developed congenital 
heart defects including VSD and ASD (129). Moreover its loss of function study 
also showed embryonic lethality caused by suppression of critical genes required 
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for cardiac development (144). Combined with those studies, the differences of 
SENP5 including substrate specificity and subcellular localization let us make the 
hypothesis that SENP5 may have unique functions in hearts, compared to SENP2. 
Interestingly, SENP5 was induced in human idiopathic heart failure, typically 
downregulated postnatally, which leads to the idea that SENP5 re-induction could 
be involved in pathologic heart development. In current study, we provide strong 
in vivo evidence for its linkage with dilated cardiomyopathy, demonstrating that 
elevated protein level of SENP5 is not protective but detrimental and pushes to 
pathologic cardiac responses.  
Mitochondrial dysfuction connecting with SUMO. Mitochondria are well known 
as an energy generator, indicating its metabolic importance in the energetic organ, 
heart. In many cases of congestive heart disease such as dilated and 
hypertrophic cardiomyopathy, mitochondrial structural and functional 
abnormalities are observed. Moreover, several point mutations in mitochondrial 
DNA coding genes have been reported as associated with cardomyopathy (145). 
Along with those genetic mutations, mitochondrial respiratory chain deficiency is a 
main functional defect (145). Cardiac SENP5 Tg showing decreased 
mitochondrial enzymatic activities was followed by mitochondrial pathology in 
dilated cardiomyopathy. Interestingly, complex IV activity was decreased in 
SENP5 Tg, which consisted of proteins encoded by mtDNA, but complex II 
activity was also reduced, which was encoded by nuclear DNA. It suggested that 
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SENP5 induced mitochondrial respiratory chain deficiency is not caused by 
genetic mutations but possibly by SENP5 mediated deSUMOylation of targets.  
      In energy metabolic view, pathologic hearts change their main energy source 
from fatty acid to glucose, reprogramming back to the early post-natal energy 
metabolism (146, 147). Consistently, SENP5 overexpressed murine hearts 
disrupted their metabolic properties. Some metabolic genes were down-regulated 
in SENP5 Tg hearts compared to WT (Figure III.14). Destroyed fatty acid 
oxidation along with increased glucose metabolism was consistent with 
dysfunctional mitochondria from the same age of SENP5 Tg. It is also supported 
by pathologically unbalanced heart, in other words, decompensated heart 
showing totally decreased metabolic gene profiles (47). Together, increased 
SENP5 protein level induces the pathologic heart.  
Mitochondrial dynamic protein sensitive to SENP5. Mitochondrial dynamics 
such as fusion and fission are correlated with heart function. In human hearts, one 
of mitochondrial fusion protein, optic atrophy 1 (Opa1) is down-regulated or 
unchanged upon ischemia or failing (148). Decreased respiratory and contractile 
function from cardiac specific double knock-out of another mitochondrial fusion 
protein, mitofusins (Mfn) 1,2 indicates that interrupting mitochondrial fusion results 
in lethal cardiac function (149). Although in human failured heart, Mfn is 
upregulated (148) it seems to be a compensatory response because Opa1 is 
remarkably reduced in the same context. Recently, the first direct relevance of 
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Figure III.14. Impaired cardiac energy metabolism in SENP5 Tg. In increasing 
need of glucose utilization, glucose metabolism related genes such as glucose 
transporter 4(GLUT4) and pyruvate dehydrogenase kinase 4 (PDK4) were 
increased but fatty acid oxidation is down-regulated through carnitine acyl 
transferase 1 (CPT1), peroxisome proliferator-activated receptor α (PPARα) and 
Estrogen-related receptors (ERRs). Those gene expression patterns are 
correlated with metabolic property of heart failure. 
	   110	  
mitochondrial fission with cardiomyopthy is reported. A mutant dynamin-related 
protei-1 (Drp-1), mitochondrial fission protein, which loses the ability of self-
oligomerization causes dilated cardiomyopathy (134). Also, the strong supportive 
studies have reported that Drp-1 is SUMO-dependently modified and its 
SUMOylation is sensitive to SENP5 (36, 37, 59). Unconjugated mitochondrial Drp-
1 was significantly increased but SUMO2/3 conjugated Drp-1 was decreased in 
mitochondrial fraction from SENP5 Tg. Usually, Drp-1 stays in the cytoplasm as a 
phosphorylated form. Once a phosphatase is activated such as calcineurin then 
dephosphorylated Drp-1 finally can move to mitochondria (150). SUMOylation is 
thought to make the stable attachment of Drp-1 to mitochondria. Thus, forced 
SENP5 expression desumoylated Drp-1, resulting in its move away from 
mitochondria. Finally, the cytoplasmic Drp-1 cannot mediate mitochondrial fission 
and causes a dramatic increase in mitochondrial size. Interestingly, dilated 
cardiomyopathy suffering patients represent remarkable number of gigantic 
mitochondria (151). It is supportive to our observation in human and murine study 
(Figure III.1) that increased SENP5 is detrimental to heart and results in dilated 
cardiomyopathy.   
      Uncontrolled fission or fusion is involved in apoptosis which is a critical 
mechanism leading to cardiomyocyte loss in heart failure. The involvement of 
mitochondrial fusion in apoptosis is controversial. Down-regulated Mfn2 induced 
apoptosis (152, 153) but overexpresed Mfn2 also causes apoptosis by 
attenuating Akt signaling (154, 155).  Conversely, the mitochondrial fission 
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triggers apoptosis, the proapoptotic factor, Bax facilitates sumoylation of Drp-1 as 
well. However, increased sumoylated Drp-1 by Bax is related to mitochondrial 
permeability transition pore (MPTP) opening rather than mitochondrial fission (156, 
157). Loss of Drp-1 in Drp-1-/- murine brain significantly increases apoptosis (158). 
Although sumoyation of Drp-1 has not been explored in this study, the number of 
highly connected mitochondria is dominant in Drp-1-/-. Thus increased apoptosis 
by SENP5 overexpression is correlated with mitochondrial dynamics, especially 
enhanced desumoylation of Drp-1. Apparently, SENP5 is an emerging new 
member, which can control mitochondrial physiology in cardiac muscle tissues. 
A novel target of SENP5 is involved in necrosis. Ultrastructural images from 
SENP5 Tg exhibited abnormal mitochondrial features including catastrophic 
mitochondria destruction and extensive swelling with loss of cristae, which is 
called as cristolysis. Those characteristic phenotypes match to necrosis. Necrosis 
is initiated in the mitochondria by breakage of Ca2+ homeostasis and oxidative 
damage (138, 159, 160). Mitochondrial Ca2+ overflow follows mitochondrial 
membrane permeability reduction and finally induces necrosis. In early study, 
necrosis is known as spontaneous cell death compared to apoptosis, 
programmed cell death. However, increasing evidence suggests that it also 
occurrs in a programmed way. Cyclophilin D has been reported as one of 
regulators in the programmed Ca2+-dependent necrosis. Its genetic deletion 
causes Ca2+-dependent necrosis because it regulates Ca2+ influx (138, 140, 143). 
Along with that concept, apoptosis inducing factor (AIF) is also proposed as a 
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necrotic factor. Although its initial role is known to regulate apoptosis, its nuclear 
translocation results in large scale DNA breakdown and chromatin condensation 
and leads to necrosis (82, 161, 162). Nevertheless, little is known about the 
mechanism to explain its nuclear translocation. Here we found that AIF was 
modified by SUMO and SENP5. Elevated SENP5 protein level both in human 
diseased heart and experimental animal heart such as SENP5 Tg reduced SUMO 
conjugation level of AIF. Consistently, nucleus-located AIF was increased in 
immunoblot and immunostaining analysis (Figure III.14). These results suggest 
several possibilities. First, SENP5 desumoylates AIF, leading to conformational 
change. It results in release of protector binding to AIF and finally results in easy 
access of proteases such as Calpain-1 into AIF. It is evident that Increased Ca2+ 
level stimulates ROS production, leading to carbonylation of AIF, which is 
associated with Calpain-1 mediated cleavage (163). Another one is that 
desumoylation by SENP5 makes high accessibility of nucleus leading sequence 
(NLS) and/or masking of mitochondria leading sequence (MLS) of AIF. The 
reason is that AIF-K59R overexpression caused high nuclear translocated AIF, to 
which MLS is adjacent (Figure III.14.c). Sequentially, AIF is able to be released 
from mitochondria, it is involved in necrosis in the nucleus as well. However it is 
still unknown largely where AIF is sumoylated and whether desumoylated AIF can 
induce necrosis and so on. Nevertheless, it should provide valuable information 
for therapeutic or preventative application of AIF in the heart failure. 
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Chapter IV 
Summary, Significance and Future Directions
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4.1. Specificity for targets: SUMO conjugation vs deconjugation.          
      Among causative genes for dilated cardiomyopathy, lamin A/C has been 
identified as a SUMO target associated with familiar dilated cardiomyopathy (105, 
106). We tested whether lamin A/C is sensitive to SENP5 using 
immunoprecipitation analysis since its PTM is SUMO2/3-dependent and its 
mutation correlates to dilated cardiomyopathy (164). Unexpectedly, cardiac lamin 
A/C sumoylation was not changed in heart specific SENP5 Tg, compared to WT. 
However, mitochondrial fission protein, Drp-1 was responsive to SENP5, known 
as SUMO-dependently modification. In calpastastin study, there were additional 
sumoylated bands not responsive to SUMO2/3. We have poor understanding 
about that but it could be due to SUMO1 conjugation to Calpastatin since stress 
condition induces SUMO1 upregulation along with SUMO2/3 in the hearts based 
on our observation. Still it is unclear whether increased SUMO1 functions as 
protective or detrimental especially to the heart. SUMOylation is tightly regulated 
by cellular availability, time and place of SUMO components. Also there are many 
different SUMO components for SUMO conjugation and deconjugation, 
suggesting maximal possible combination for efficient regulation.  Recent study 
supports this idea, in which SENP3 has modulated Drp-1, promoting brain cell 
death after ischemia (165). In that study, ischemia has up-regulated SENP3 but 
not SENP5 in the brain. This is a totally different response, compared to our 
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observation in the hearts. Thus it indicates that variable SUMO pathway 
components makes different preferences to the same target in a tissue- or time-
dependent manner for fine-tune regulation.  
4.2. Cardiomyocyte death by SUMO2/3.  
      Previously, among death factors, caspase-2, 7 and 8 have found to be 
modified by SUMO1 for their nuclear localization and self-activation (166-168). 
Also, it has been suggested that reactive oxygen species (ROS) influence 
desumoylation enzymes such as SENP3 (130). Oxidative cell death is very 
sensitive to cellular sumoylation level and their targets such as JNK and 
homeodomain-interacting protein kinase 2 (HIPK2) (169, 170). Furthermore, 
SUMO1 has conjugated to nuclear factor κB (NFκB) regulator inhibitory κBα 
(IκBα) for protective function but in contrast, associated with NFκB essential 
modulator (NEMO), for activation (171-173). Those all indicate that SUMO 
dependent modification correlates with cell death.      
      Nevertheless, it is largely unknown whether SUMO2/3 is involved in cardiac 
muscle cell death or not. We observed that human and experimental animal heart 
failures have enhanced SUMO2/3 level (Figure II.1) and E3 ligation enzyme, 
PIAS2 (Figure II.17), suggesting that hypersumoylation response is possibly 
explained by altered fortification of SUMOylation components. Apparently SUMO2 
overexpressed murine hearts have undergone to exaggerated apoptosis. It has 
long been suggested that cardiomyocyte death is sufficient to facilitate heart 
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failure by cardiac muscle cell loss. Therefore, current studies demonstrate that 
SUMO2/3 is critical for modulating cell death pathway. Moreover, they propose 
the new concept of SUMO2/3 for Ca2+ dependent protease system, Calpain2-
Calpastatin. In this context, elevated SUMO2/3 conjugation activity hits both 
Calpain2 and Calpastatin then, induces cell death through synergistic effects by 
releasing active Calpain2 from its inhibitor and by suppression of inhibitory 
Calpastatin via changed stability, subcellular localization and interaction ability. 
Additionally, SUMO2/3 induced Calpain2 activation has been further confirmed by 
accumulation of cleaved caspase-12, leading to activation of caspase-9 and -3 
(80, 81). Calpain2 and Calpastatin -mediated cell death could cause further 
degradation of cardiac structural proteins including the actin and the tropon T, 
leading to contractile dysfunction. But there are still remained questions that exact 
SUMO2 conjugation sites on Calpastatin and definition of additional slow running 
bands not matching with SUMO2/3 –dependent modification for both Calpain2 
and Calpastatin remain to be identified. Careful identification of those unsolved 
questions would help to define the mechanism and to design drugs for heart 
failure.   
4.3. Mitochondrial cell death with SUMO protease, SENP5.    
      Prominent alterations observed in α-MHC promoter driven SENP5 
overexpression have been swollen mitochondria with disorganized cristae, 
accompanied by reduced mitochondrial enzymatic activities. Those impaired 
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mitochondrial respiratory chain with mitochondrial morphologic defects has been 
reported as apparent properties of pathologic hearts including failing rat hearts 
after aortic constriction and hypertrophic cardiomyopathy of pig (174, 175). Also 
specific PTM such as nitrosylation and O-linked glycosylation in mitochondria 
have been suggested that reversible modification of mitochondrial proteins results 
in pathologic hearts (176, 177). Here, we proposed SUMO-dependent PTM of 
mitochondrial proteins to be critical for mitochondrial function. Especially, recent 
findings have supported that it is possible that mitochondrial proteins would be 
modified by SUMO pathway through mitochondrial SUMO E3 ligase, MAPL (17), 
SUMO1 and SENP5 (36, 37, 59). Mitochondrial fission protein, Drp-1 has been 
altered by many different modifications including PKA, CaM kinase Iα and 
calcineurin (150, 178-182). In addition, SUMO1 conjugation to Drp-1 results in 
mitochondrial fragmentation by stabilizing Drp-1 to localize in mitochondria. We 
found that heart specific overexpressed SENP5 caused decreased mitochondrial 
fission and finally led to giant mitochondria. The huge mitochondrial size is one of 
the prominent phenotypes in early cardiomyopathy. Although end stage of heart 
failure developed small fragmented mitochondria, early adaptive response such 
as hypertrophied heart has revealed enlarged mitochondria. Enlarged 
mitochondria in the hypertrophied heart have been further supported. Drp-1 has 
been increased in diseased hearts (148) although relative SUMO association 
level of Drp-1 was not explored. We found that SUMO-deconjugated Drp-1 has 
been also remarkably increased in SENP5 overexpressed murine hearts. 
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Together, impaired SUMOylataion especially for Drp-1 by forced SENP5 
expression directs mitochondrial dynamics into less pro-fission. Consistent with 
previous Drp-1 deficent animal studies representing giant mitochondria and 
dilated cardiomyopathy (134), this finding makes us conclude that dysregulated 
mitochondrial fission fails to maintain mitochondrial function, finally leading to 
pathologic hearts. At this moment, we still do not understand whether uncontrolled 
SUMOylation in Drp-1 is sufficient to cause dilated cardiomyopathy, also 
increased Drp-1 expression has resulted in controversial cell death outcomes 
(156, 183, 184). However, at least our study could add one possibility that 
mitochondrial SUMO conjugation cycle regulates mitochondrial dynamic protein 
by pulling Drp-1 into mitochondria and likely associating Drp-1 with fission prone 
membrane-receptor, Fis1 rather than Mfn (mitofusin).  
      We also have a poor understanding of how unbalanced mitochondrial SUMO 
conjugation by SENP5 resulted in cell death. Here, AIF has been proposed as a 
novel SENP5 target. Especially, AIF is attractive as a target because it has been 
known to involve in caspase-independent apoptosis in many different tissues (162, 
185). Sequential subcellular localization of AIF is important for its biologic 
functions including respiratory chain stabilization and pro-apoptotic properties (83, 
186) but processing for different subcellular localization of AIF has been largely 
unknown. Calpain1 and cathepsin B, L or S have been well known proteases 
mediating cleavage of AIF (187-189) but still their regulation has not been applied 
yet. Cardiac AIF has been modified SUMO-dependently in murine hearts (Figure 
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III.13). In addition, nuclear accumulated AIF has been predominant upon 
enhanced SENP5 expression in the hearts. At this moment, we still do not 
understand exact association of SUMO conjugation with AIF but we suggest the 
following mechanisms. First, decreased SUMO conjugation of AIF makes its 
conformational change, which might cause easy access for proteases. Second, 
different level of SUMO conjugation could block mitochondrial leading sequence 
(MLS) or expose nuclear leading sequence (NLS) of AIF for induction of nuclear 
accumulation. Third, SUMOylation intensity in AIF might affect not only its 
subcellular localization but also its nuclear partners such as Endonuclease G 
mediating DNA degradation or chromatic condensation.  
      We have a poor understanding of how and where AIF was modified by 
SUMO-dependent PTM, although it seems to occur in mitochondria because AIF 
usually exists in mitochondria for mitochondrial complex I maintenance in normal 
state (190).  A recent interesting study showed that necrosis can also be 
programmed (191) but little is discovered as required trigger molecules. Moreover, 
our preliminary data indicate that AIF seems to be poly and/or multiple-
sumoylated and is also sensitive to SENP2 in vitro, indicating that SUMO-
dependent PTM of AIF is regulated as complicated ways and their involvement in 
necrosis is tightly controlled by SUMO pathway. Further investigation into the 
effectiveness of SUMOylation or deSUMOylation may provide important insights 
into AIF mediated programmed necrosis.   
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4.4. Cardiomyocyte proliferation and SUMO. 
      Increased SUMO2 or SENP5 level in the hearts results in decreased cardiac 
muscle cell proliferation accompanied by increased cell death, correlating with 
congenital heart disease. It has been shown that SUMO is also critical for cell 
division. In those studies, SUMO-dependent PTM has repressed cyclin D1 and 
arrested G1 cell cycle through modification of Stra13 (192) or activated cell cycle 
by enhancing nuclear protein, RanGAP1-RanBP2 interaction (193). However, 
SUMO2/3-dependent PTM mediated cell proliferation is less studied although 
SUMO protease, SENP5 has been suggested to be required for cell proliferation 
(36, 57). Intriguingly, these results are quite different from our observation, lower 
cardiomyocytes proliferation upon promoting SENP5 expression (Figure III.5). 
The discrepancy might be because our observation has been from in vivo animal 
model and tissue-specific effect, as well as depended on its threshold level. 
Recently, a very interesting study has provided a critical clue that AMPKβ is 
specifically modified by SUMO2 (125) and that activated AMPK has suppressed 
cell proliferation (127). It is possible that heart specific SUMO2 enhancement 
might affect AMPK activity, resulting in cell cycle arrest. 
      In SENP5 study, decreased cardiac muscle cell division has been also shown  
(Figure III.5). In Drosophila study (126, 127), reduced mitochondrial complex I 
activity has caused ROS, finally leading FOXO activation. Activated FOXO has 
been suggested as a regulator of cell cycle to repair DNA damage by turn-on of 
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proteins involved in tolerance to oxidative stress (194, 195). Here, we proposed 
AIF as a novel target of SUMOylation. AIF has dual function including 
mitochondrial respiratory chain and caspase-independent cell death. Its loss of 
function study has revealed unstabilized mitochondrial respiratory complexes and 
higher ROS. Based on this result, it could be assumed that the liberal AIF 
detached from mitochondria increase through SENP5 overexpression might 
promote unstable mitochondrial complex I assembly. Disarrayed complexes 
should cause mitochondrial function drop, leading to cardiomyocyte division stall. 
This idea awaits further investigation.  
      In summary, we provide the first evidence that covalent conjugation of 
SUMO2/3 or deconugation by SENP5 is a new regulatory strategy for 
cardiomyocyte survival and congestive heart disease. Especially, these 
observations open up new roads not only for understanding SUMO2/3 
conjugation in stressed hearts, but also for identifying how SUMO2/3-dependent 
conjugation can provide valuable evidence for adult cardiac disorders.  
4.5. Implication for human disease.   
      Cardiac hypertrophy is initially beneficial for heart against overloaded work. 
However, sustained responses finally lead to heart failure and sudden death. 
During adaptive response, postnatal hearts adapt to those stresses via a variety 
of reactions including increasing cardiomyocyte size and reactivation of fetal 
cardiac genes. Thus, those kinds of changes are used as cardiac stress indicators 
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for diagnosis. Here, we demonstrate that cardiac muscle loss is accelerated by 
covalent SUMO2/3 attachment to targets such as Calpain-Calpastatin system. 
Also, overexpression of the deconjugation protease, SENP5 contributes to failed 
mitochondrial function, leading to dilated cardiomyopathy. Similar observation was 
proposed in cancer cells and those patterns have been used as diagnostic 
markers (196). Thus it should be also used as a new diagnostic biomarker for 
stressed heart.  
      SUMO-dependent PTM has been applied in a number of cellular processes as 
well as diseases such as neurodegenerative disease (197), and cancers including 
breast and colon cancer, and myeloma (197, 198). Moreover, a recent study has 
indicated that SUMOylation is required for c-Myc driven tumorigenesis (199) and 
heat shock response (200). In spite of these attractive properties, there is little 
report related to the inhibitor. To date, ginkgolic acid and kerriamycin B are the 
most famous inhibitors of SUMO E1 enzyme (201, 202). Nevertheless, recent 
emerging studies have been interested in inhibitor development with more 
specificity and variety targets (203, 204), as well as high throughput screening 
assay to seek inhibitors efficient development of inhibitors (205). However, the 
difficulty to solve is how each inhibitor involving specific SUMOylation provides 
specificity for substrates in whole proteome because the same SUMO isoform 
conjugation does not make the same effect of protective or pathological. For 
example, SUMO2 is required for nuclear integrity through conjugation of lamin 
A/C, but not for cell survival because increased SUMO2 conjugation to Calpain-
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Calpastatin system causes cell death. Our heart specific SUMO2 or SENP5 Tg 
will allow a detailed analysis to find its targets in diseased state. Furthermore the 
information obtained from those cardiac specific Tg should be valuable to design 
potential therapeutic drug with no side effect to ameliorate heart disease 
progression.  
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